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Introduction 
1 Morphology of the stomach and gastric mucosa 
The stomach may be divided into three parts. The cardia is a narrow zone bordering 
the oesophagus characterised by mucus secreting cells and the absence of parietal and 
chief cells. The body of the stomach consists of the fundus and corpus with the acid 
producing or oxyntic mucosa. This part of the mucosa produces hydrocloric acid and 
numerous regulatory peptides. In the antrum (or pyloric part of the stomach) the 
mucosa mainly consist of mucus cells. The G cells of the antrum produce the acid 
secretagogue hormone gastrin. 
The stomach, like other parts of the gastrointestinal (GI) tract, consists of four 
principal layers: mucosa, submucosa, muscularis and serosa. The mucosal cells are 
organised in glands. The tissue between the glands in the mucosa is called lamina 
propria and contains blood vessels and lymph vessels, nerves and connective tissue. 
The muscularis mucosae is located below the bottom of the gastric glands and forms 
the boundary to the submucosal layer. Outside the submucosa, the stomach wall 
consists of two muscle layers and an outer serosal layer. 
The morphology of the gastric mucosa has been thorougly reviewed by Helander 
(Helander 1981). The glandular mucosa of the mammalian stomach invaginates the 
lamina propria, forming the gastric pit on the luminal surface and the gastric glands 
from the bottom of the pits. Each oxyntic gland is divided in to three regions: the 
isthmus, the neck and the base. Two main types of cells (exocrine and neuroendocrine 
(NE)) can be found in the gastric gland (Figure 1). The neck and isthmus region is 
also referred to as the proliferative or regenerative zone and harbours endodermal 
stem cells, which may be the origin of all cells in the mucosa (Modlin et al 2003a). 
The stem cells proliferate and produce linage precursors that differentiate into the 
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different mucosal cell types of the gastric mucosa (Karam 1995). As these stem cells 
divide, they migrate upwards or downwards as they differentiate into the different cell 
types. 
 
Figure 1: Schematic illustration of a glandular unit from the oxyntic mucosa (modified from 
(Karam et al 2001)). 
1.1 Exocrine cells 
Surface mucous cells cover the surface of the gastric mucosa and the gastric pits, and 
secrete mucus and bicarbonate. In the neck and isthmus region mucus neck cells and 
endodermal stem cells are found. Chief cells secrete pepsinogen, which is a precursor 
of the proteolytic enzyme pepsin. They are found in the basal part of the oxyntic 
glands (Helander 1981). 
The dominant cell population in the oxyntic mucosa are the hydrochloric acid-
secreting parietal cells. They may be found in all parts of the glands, but are most 
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numerous in the middle third. The apical cell membrane has tubular invaginations, 
thus increasing the surface. Acid is secreted by the gastric H+/K+-ATPase (proton 
pump) which is translocated to the apical secretory canaliculi upon stimulation, by 
fusion of the cytoplasmatic tubulovesicles holding the proton pump in the resting 
state. The proton pump (H+/K+-ATPase) can be used as a marker for parietal cells. 
The transport of protons from the interior of the cell to the glandular lumen is highly 
energy-consuming, and parietal cells contain an unusually high number of 
mitochondria. 
1.2 NE cells 
The NE cells constitute about 2% of the cells in the gastric mucosa (Bordi & D'Adda 
1991). They are usually situated in the lower half of the glands and are classified into 
open type cells (cells extending to the gastric lumen) and closed type cells (cells not 
reaching the lumen) (Capella et al 1991). 
About 65-75% of the NE cells in rat oxyntic mucosa are enterochromaffin like (ECL) 
cells (Håkanson et al 1976). The corresponding number in man is 30-35% (Simonsson 
et al 1988). Like other gastric NE cells, the ECL cells are predominantly located in 
the basal half of the glands, and ECL cells are capable of self-replication (Tielemans 
et al 1989; Ryberg et al 1990). The main function of  the ECL cells is production of 
histamine which stimulates acid secretion. Biosyntesis of histamine is done in the 
cytosol by histidine decarboxylase (HDC) (Modlin & Tang 1996). Both histamine and 
HDC are used as ECL cell markers. However, histamine and HDC are also found in 
mast cells (Suzuki-Ishigaki et al 2000), thereby somewhat reducing the specificity for 
ECL cells in the oxyntic mucosa. ECL cells exhibit a characteristic ultrastructure, 
with a large eccentric nucleus surrounded by numerous electron-dense granules and 
electron-lucent vesicles (Tanabe et al 2003). Histamine is sequestered in secretory 
vesicles by the vesicular monoamine transporter type 2 (VMAT-2). In addition to 
histamine, the secretory granules of ECL cells also contain chromogranin A (CgA) 
(Capella et al 1991) and pancreastatin (product of CgA), which are both released into 
the blood stream (Syversen et al 1994; Håkanson et al 1995).  
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In the stomach the gastrin cells (G cells) are exclusively located in the antral mucosa 
and are found in the mid portion of the glands (Sundler & Håkanson 1991). G cells 
are also found in the duodenum (Rehfeld & van Solinge 1994), but only the antral G 
cells seem to participate in the regulation of gastric acid secretion. G cells are of the 
open type and the luminal surface is capable of responding to gastric luminal content. 
The G cells' main function is to synthesise gastrin, which makes the G cells essential 
in the regulation of both gastric acid secretion and growth of the oxyntic mucosa. 
Gastrin is released into blood from secretory granules along the basolateral 
membrane, which is close to mucosal blood vessels (Larsson 2000). 
D cells are found both in the antrum, where the open type predominate, and corpus, 
mainly as closed cell type (Holst 1991). They secrete somatostatin (SST), a regulatory 
peptide hormone which inhibits numerous physiological processes. It inhibits gastrin 
release from the G cell, histamine release from the ECL cell and hydrochloric acid 
secretion from the parietal cell. In addition the somatostatin peptide plays an 
important role in the control of cell proliferation in normal and tumourous tissue 
(Patel 1997). The D cells are prototypical paracrine cells and have long cytoplasmatic 
processes that directly contact neighbouring cells (Larsson et al 1979).  
Enterochromaffin (EC) cells are distributed all along the GI tract and play a pivotal 
role in several aspects of gut function including secretion, motility and sensation 
(Sjölund et al 1983; Gershon 1999). The EC cells show argyrophilia (Dawson 1948) 
and synthesise, store and release the biogenic amine serotonin, or  
5-hydroxytryptamine (5-HT) (Rapport et al 1948). These cells are found both in the 
antrum and the corpus. They constitute about 25% of the gastric NE cells in man 
(Simonsson et al 1988), but are nearly absent in rat stomach (Capella et al 1991). The 
EC cells are belived to function as sensory transducers that activate mucosal processes 
of both intrinsic and extrinsic primary afferent neurones through their release of 
serotonin (Gershon 1999; Lundgren 2000). Secreted serotonin may also influence 
adjacent cells by paracrine actions and exert hormonal effects on distant cells via the 
blood circulation. 
A-like cells are found predominantely in the oxyntic mucosa. At the ultrastructural 
level the secretory granules resemble those of the pancreatic glucagon (A) cell. 
Recently, the peptide ghrelin has been localised to the A-like cells in rats and humans 
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(Kojima et al 1999; Date et al 2000). The most important role of ghrelin appears to be 
stimulation of appetite and regulation of energy homeostasis. Ghrelin has also been 
suggested to play a role in regulation of gastric acid secretion (Peeters 2005). It 
appears to be an endocrine signal, possibly reaching the central nervous system via 
the bloodstream. However, it also uses neural pathways, in particular the vagus 
(Peeters 2005).  
2 The NE system 
The diffuse NE system can be defined as a set of cells which are diffusely dispersed in 
several organ systems including the GI and respiratory systems (Langley 1994). More 
than twenty different types of NE cells are found throughout the body, and common 
features of them are: the production of signal substanses such as regulatory peptides 
or bioactive amines, the presence of dense-core secretory granules from which the 
hormones are released by exocytosis in response to an external stimulus, and the 
absence of axons and synapses (Langley 1994). 
NE cells have mainly two specific tasks; synthesis of peptide hormones and uptake of 
amino acids and transformation of these into biogenic amines by decarboxylation. 
Thus, the NE cells are also known by the acronym APUD (amine precursor uptake 
and decarboxylation) (Pearse 1969). The embryological origin of the NE cells is 
disputed. Because these cells show many similarities with neurons, it was claimed that 
they all originated from the neural crest (Pearse & Polak 1971). This was found not to 
be the case for all NE cells (Le Douarin 1988). The common theory today is that also 
these cells derive from a common endodermal stem cell (Fontaine & Le Douarin 
1977; Rawdon & Andrew 1993; Andrew et al 1998; Montuenga et al 2003). 
However, this has not been fully determined (Andrew et al 1998; Waldum et al 1999). 
The gastroentero-pancreatic system is the richest source of regulatory peptides outside 
the brain (Polak & Bloom 1986). Due to common cytochemical and functional 
characteristics, the pancreatic islet cells and other endocrine cells of the gut, including 
the EC cell, were brought together by Pearse (Pearse 1969). Today, the ECL cell in 
the oxyntic mucosa is probably the best characterised NE cell (Waldum et al 1996b). 
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In pancreas, the endocrine tissue (the pancreatic islets of Langerhans) is composed of 
four different cell types, α, β, δ and PP cells. These cells produce the hormones 
glucagon, insulin, somatostatin, and pancreatic polypeptide (PP), respectively. Under 
physiological conditions, the pancreatic islets control blood glucose homeostasis.  
2.1 NE markers 
CgA and its product pancreastatin are found in a variety of NE cells and are widely 
used as general markers of NE cells (Nobels et al 1998; Wick 2000). CgA is an acidic 
secretory glycoprotein that belongs to the granin family (Taupenot et al 2003). It is 
expressed in most types of NE cells and in most NE tumours (Nobels et al 1998; 
Wick 2000). CgA is typically bound to the membrane of the NE secretory granules. 
Its precise biological functions are not fully elucidated, but there is a number of 
hypotheses (Gorr et al 1987; Syversen et al 1994; Nobels et al 1998): CgA is thought 
to be a precursor to biologically active peptides with autocrine, paracrine and/or 
endocrine functions. One of these peptides is pancreastatin, which has a regulatory 
effect on secretion of both endocrine and non-endocrine cells (Nobels et al 1998). 
CgA itself appears to modulate the proteolytic processing of peptide hormones and 
neuropeptides. This glycoprotein takes part in the condensation of the content of 
secretory granula (Huttner et al 1991). It also may play a part in the osmotic 
regulation. 
Other general markers are synaptophysin (SYN) and neuron-specific enolase (NSE). 
SYN has been identified as an integral membranous glycoprotein of pre-synaptic 
vesicles in neurons and in NE cells (Wick 2000). It is expressed by a variety of 
normal and neoplastic NE cells and is therefore used as a marker of NE differentiation 
in various tumours. It has also been found in non-NE tumours, and should therefore 
not be used alone to characterise NE differentiation, but in addition to e.g. CgA (Wick 
2000). NSE is a soluble neuronal protein which is known as a cell specific isoenzyme 
of the glycolytic enzyme enolase (Marangos & Schmechel 1987). It is used as a 
marker of NE cells, although less specific than CgA (Lloyd 2003). 
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Histamine and HDC, SST, and serotonin can be used as specific markers for the NE 
ECL cells, D-cells and EC-cells, respectively. Moreover, VMAT-2 can be used as a 
marker of ECL-cells, although not being entirely ECL cell specific (Zhao et al 1997). 
3 Control of gastric acid secretion 
3.1 Gastrin and histamine 
Gastrin was the second hormone postulated to exist (Edkins 1905), and gastrin-17 was 
finally characterised by Gregory and Tracy in 1964 (Gregory & Trazy 1964). 
Preprogastrin is rapidly altered during translation to generate progastrin, which is 
cleaved to generate the COOH-terminal Gly-extended gastrins (G34Gly, G17Gly). 
These are then converted to their corresponding COOH-terminally amidated peptides 
G34 and G17 which act at the cholecystokinin-2 (CCK-2, or gastrin-CCKB) receptor. 
Postprandial increase in acid secretion is mediated by the release of gastrin (Walsh 
1994; Beltinger et al 1999). Gastrin releases histamine from the ECL cells and this 
histamine subsequently stimulates the parietal cells directly to produce acid (Figure 2) 
(Waldum et al 1991b; Shankley et al 1992).  
In addition, gastrin increases histamine synthesis and storage in ECL cells by inducing 
the expression of HDC and VMAT-2. CgA mRNA abundance is also regulated by 
gastrin (Dimaline et al 1993). Gastrin receptor mRNA has been found expressed in 
parietal cells (Tømmerås et al 2002), but observations are diverging and there is no 
consensus on the question of a direct effect by gastrin on the parietal cell. In mice in 
which the gastrin gene has been deleted, the parietal cells are immature, and there is 
reduced acid secretion and insensitivity to acute secretagogue stimulation (Koh et al 
1997; Friis-Hansen et al 1998). An infusion of gastrin reverses the insensitivity, 
suggesting that gastrin regulates the final steps in parietal cell maturation, which 
might be mediated by CCK-2 receptors expressed on these cells. 
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 Figure 2: Schematic illustration of the main cells and mechanisms regulating gastric acid 
secretion (modified from (Waldum et al 1998b)). 
3.2 Somatostatin 
This peptide is widely expressed throughout the central and peripheral nervous 
systems and in peripheral tissues (Olias et al 2004). Somatostatin (SST) regulates 
neurotransmission in the brain, and secretory processes in the anterior pituary gland, 
the pancreas, and the GI tract. SST is released from D cells and is the main inhibitor 
of histamine release, shown by studies on the vascularly perfused stomach (Sandvik & 
Waldum 1988; Fykse et al 2005) and isolated ECL cells (Lindström et al 1997). 
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Five subtypes of somatostatin receptors (SSTR) are known at the present. These five 
subtypes of SSTR belong to the superfamily of G-protein coupled receptors that have 
seven transmembrane domains (Patel 1997). SSTRs are found in a range of tumour 
cell lines and are expressed in most human NE tumours. Different SST analogs (e.g. 
octreotide) are widely used both in diagnosis and therapy of these tumours. 
Functionally, somatostatin inhibits gastrin release by binding to the somatostatin 
receptor 2 (SSTR-2) on the ECL cells (Borin et al 1996).  
3.3 Vagal activity 
The nervous system is implicated in the regulation of gastric acid secretion (Walsh 
1988). Activation of the vagal nerves and subsequent stimulation of postganglionic 
cholinergic fibers can stimulate gastric acid secretion by a direct effect of acetylcholin 
on muscarinic receptors type 3 on the parietal cells (Pfeiffer et al 1990; Sandvik et al 
1998). Intrinsic neurons also contain different peptides, such as pituitary adenylate 
cyclase activating peptide (PACAP), gastrin releasing peptide (GRP), galanin and 
vasoactive intestinal peptide (VIP). They innervate the D, ECL and parietal cell of the 
oxyntic mucosa. PACAP induces histamine release from ECL cells via the PACAP-1 
receptor (Pisegna et al 2000; Sandvik et al 2001). It has also become apparent that 
PACAP is even more potent than gastrin in the stimulation of ECL cell proliferation 
(Lauffer et al 1999). GRP seems to have a dual role in regulation of acid secretion. 
The vagal nerves stimulate gastrin release via GRP. The gastrin release is balanced by 
GRP stimulated release of somatostatin from D-cells. Inhibition of gastric acid 
secretion induced by the GRP-homologue bombesin is found to be SSTR-2 receptor-
mediated (Piqueras et al 2003). A recent study found that bombesin-induced release 
of gastrin was potentiated by a somatostatin antagonist, suggesting that the G cells 
posess SSTR-2 receptors and further indicating a SSTR-2 receptor-mediated 
inhibition of gastrin release (Fykse et al 2005). Moreover, GRP may inhibit ECL cell 
histamine output indirectly by stimulating SST release from corpus D-cells. Galanin is 
a negative neural regulator of the ECL-cell (Zeng et al 1998). 
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4 Control of proliferation 
Gastrin has a general trophic effect on the corpus mucosa (Ekman et al 1985; Havu 
1986). In addition to the general trophic effect, gastrin has a specific and pronounced 
effect on proliferation of ECL-cells (Koh & Chen 2000). There is evidence that 
gastrin might act directly on ECL cells via the CCK-2 receptor to stimulate their 
proliferation (Mahr et al 1998). In rats and mice, it has been well demonstrated that 
ECL cells are able to undergo self-replication (Ryberg et al 1990). Gastrin also 
increases the proliferation rate of stem cells in the mucosal progenitor zone (Ryberg et 
al 1990), and a role for gastrin in differentiation of the gastric progenitor cells into the 
different mucosal cell lineages, particularly the parietal cell lineage, has been 
proposed (Friis-Hansen et al 1998). The general trophic effect of gastrin may be due 
to a direct action on the endodermal-derived stem cell, although the gastric stem cells 
have not yet been conclusively shown to express the CCK-2 receptor. This suggests 
that the general trophic effect may also be mediated indirectly by substances released 
from other target cells expressing the CCK-2 receptor, e.g., the ECL cell (Waldum et 
al 1991c; Miyazaki et al 1999; Dockray et al 2001).  
Gastrin activates several paracrine cascades downstream of the CCK-2 receptor. The 
epidermal-like growth factor (EGF) family members and regenerating gene protein 
(Reg) have attracted particular attention because they may mediate some of the effects 
of gastrin on cell proliferation (Fukui et al 1998; Higham et al 1999; Miyazaki et al 
1999; Varro et al 2002b). In both experimental animal models of hypergastrinemia 
(omeprazole-treated rats), and in patients with hypergastrinemia (pernicious anemia) 
there is increased expression of gastric Reg (Fukui et al 1998; Higham et al 1999). In 
both rat and man, Reg is expressed in ECL cells, but in human stomach it is also 
found in chief cells. Reg increases proliferation of gastric epithelial cells and 
mutations of Reg are also associated with ECL cell carcinoid tumours (Fukui et al 
1998; Higham et al 1999). Moreover, in trangenic mice that overexpress Reg there is 
increased differentiation of parietal and chief cells (Miyaoka et al 2004). In a model 
system designed to allow studies of paracrine signalling pathways there is evidence 
that gastrin acts via shedding of heparine-binding epidermal-like growth factor (HB-
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EGF) to stimulate proliferation (Miyazaki et al 1999; Varro et al 2002b). Gastrin may 
also stimulate HB-EGF gene expression (Sinclair et al 2004).  
There are studies demonstrating that ECL cells both secrete and are stimulated by 
transforming growth factor α (TGF-α) (Lawton et al 1996; Modlin et al 1996). Basic 
fibroblast growth factor (BFGF) is thought to be secreted by the ECL cells and is 
found in the majority of human ECL cell hyperplastic lesions and carcinoid tumours 
(Bordi et al 1994). It is postulated to have autocrine properities as it increases the 
number of ECL cells in culture (Mahr et al 1998). Recent findings indicate that 
gastrin, acting via CCK-2 receptors, also regulates the expression of a number of 
genes in gastric mucosa that potentially influences the organisation of the mucosa, 
including a trefoil factor, matrix metalloproteinases and inhibitors of extracellular 
proteolysis (Wroblewski et al 2002; Varro et al 2002a; Khan et al 2003). 
In addition to inhibition of histamine release, somatostatin also inhibits mucosal 
growth. The SST analogue octreotide inhibits ECL cell proliferation (Raynor et al 
1993; Tsutsui et al 1995; Bakke et al 2000; Fykse et al 2004) and has been shown to 
reduce serum gastrin concentration in hypergastrinemic mastomys (Modlin et al 
1992). 
Recent work indicates that progastrin and biosyntetic intermediates with C-terminal 
Gly (G-Gly) stimulate the proliferation of a varity of tumour cells through 
mechanisms independent of the CCK-2 receptor (Hollande et al 1997; Singh et al 
2003).  
5  Tumours of the gastric mucosa 
5.1 Adenocarcinomas 
Gastric adenocarcinoma is the second most common cancer worldwide. Despite a 
decreasing incidence, gastric cancer accounts for 3-10% of all cancer related deaths 
(Crawford 1994). Ninety percent of all tumours of the stomach are malignant, and 
gastric adenocarcinoma comprises 95% of the total number of malignancies 
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(Schwartz 1996). Curative therapy involves surgical resection. The overall 5-year 
survival rate of patients with resectable gastric adenocarcinoma ranges from 10-30% 
(Harrison et al 1998; Msika et al 2000; Green et al 2002). 
Currently diagnosis of gastric cancer requires histopathologic examination of tissue or 
cytologic assessment of gastric brushing/washing. Several classification systems have 
been proposed to aid the description of gastric cancer either through macroscopic  
features or on the basis of microscopic structure. The two most commonly used are 
the Laurén and World Health Organization (WHO) systems (Fenogilo-Preiser et al 
2000). 
The Laurén classification divides gastric cancer into two major histologic types: 
intestinal and diffuse (Laurén 1965). This system describes tumours on the basis of 
microscopic features. Diffuse-type cancers have noncohesive tumour cells diffusely 
infiltrating the stroma and often exhibit deep infiltration of the stomach wall with little 
or no gland formation (Fenogilo-Preiser et al 2000; Werner et al 2001). In comparison 
to intestinal-type gastric cancers, diffuse-type gastric cancers are less related to 
environmental influences, have increased in relative incidence, occur more often in 
young patients, more common in women, and are associated with worse prognosis 
(Fenogilo-Preiser et al 2000). Intestinal-type cancers show recognisable gland 
formation and are belived to arise secondary to chronic atrophic gastritis (Fenogilo-
Preiser et al 2000; Werner et al 2001).  
Helicobacter pylori infections and autoimmune gastritis are the most common 
predisposing conditions to gastric cancer. If gastritis persists, gastric atrophy occurs 
followed by intestinal metaplasia, which in turn may lead to dysplasia and eventually 
carcinoma.  
Some studies have suggested that a proportion of gastric adenocarcinomas develop 
from the ECL cell, especially those classified as diffuse type according to Laurén 
(Waldum et al 1991a; Waldum et al 1998a). Gastric adenocarcinomas are associated 
with hypergastrinemia (Rakic et al 1991), and the association is particularly strong in 
patients with severe hypergastrinemia secondary to chronic gastritis, without or with 
pernicious anemia (Borch et al 1985; Sipponen et al 1985; Hsing et al 1993; Kokkola 
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et al 1998). Furthermore, some gastric adenocarcinomas in hypergastrinemic patients 
show signs of NE differentiation (Qvigstad et al 2002). 
Several factors have been associated with increased local recurrence and decreased 
survival in gastric carcinoma. Putative tumour markers (p53, E-cadherin, CD-34, c-
ErbB2, CA 72-4, CEA, c-met, K-sam) have recently gained popularity as potential 
prognostic indicators for predicting tumour behavior (Starzynska et al 1996; Allgayer 
et al 2000; Pinto-De-Sousa et al 2001; Gaspar et al 2001; Lee et al 2002). Of these, 
only E-cadherin has been linked definitively as a marker of heriditary diffuse gastric 
cancer (Machado et al 1999; Ascano et al 2001). These markers are likely to gain 
importance as the field of gene-expression analysis continues to expand (Starzynska et 
al 1996).  
5.2 Carcinoids 
Gastric carcinoid tumours arise from proliferating ECL-cells. Elevated levels of 
plasma gastrin initiate and maintain neoplastic change in these cells (Gough et al 
1994). The basis of the hypergastrinemia is usually hypoacidity due to chronic 
gastritis, but it can also be caused by a gastrin-secreting neoplasm. The sequence 
hyperplasia, dysplasia and neoplasia characterises the progression (Solcia et al 1988). 
Carcinoid tumours are distinct from adenocarcinomas in their biological behavior and, 
in general, exhibit a relatively favourable outcome. Gastric carcinoids are reported to 
comprise 8.7% of all GI carcinoid tumours (Modlin et al 2003b).  
Gastric ECL cell carcinoids have been classified into three types (Rindi et al 1993). 
Type I carcinoid tumours are associated with chronic atrophic gastritis, which is 
characterised by chronic inflammation of the oxyntic mucosa resulting in atrophy of 
the oxyntic glands and achlorhydria with hypergastrinemia. It often occurs in 
association with autoimmune diseases such as pernicious anemia. This is the most 
common type of gastric carcinoid. They are usually small, multicentric and often 
localised to the fundus. Type II carcinoids are associated with Zollinger-Ellison 
syndrome (ZES) and type I multiple endocrine neoplasia (MEN-1); type II carcinoid 
is less common than type I, and tumours are usually small and multiple. The 
prognosis is intermediate between the relatively aggressive type III carcinoids and the 
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more benign tumours of type 1 (Rindi et al 1993). Both type I and type II are related 
to gastrin, are considered semi-malignant, but also have metastatic potential (Borch et 
al 1985). Type III sporadic carcinoid tumours are usually single, isolated tumours 
arising in normal gastric mucosa (Lehtola et al 1985). They are not associated with 
hypergastrinemia, and are thus independent of the trophic stimulus of gastrin (Modlin 
& Tang 1996). Metastatic spread is common for this type of carcinoid.  
Poorly differentiated, high grade NE carcinomas comprise a distinct, potentially 
unrelated subset of gastric carcinoids. Some have found that the majority of patients 
with such tumours also have chronic atrophic gastritis and hypergastrinemia (Rindi et 
al 1993), implying that these more aggressive carcinomas could have carcinogenetic 
pathways in common with ECL cell carcinoids. Several decades ago, it was suggested 
that there is a morphological continuum, ranging from adenocarcinomas to typical 
carcinoids (Bates & Belter 1967). 
5.3 Consequences of hypergastrinemia 
”The gastrin concept” (hypoacidity→hypergastrinemia→ECL cell 
hyperplasia→carcinoid), explaining the relationship between hypergastrinemia 
induced by acid hypo secretion and gastric carcinoids, has been known for several 
years (Håkanson & Sundler 1990). Whereas the role of gastrin in the ECL cell 
hyperplasia-dysplasia-neoplasia sequence is well documented in rodents (Ekman et al 
1985; Poynter et al 1985; Havu 1986), it is more difficult to study in humans as the 
time perspective of carcinoids is prolonged, and also due to confounding factors. 
However, gastrin induces ECL cell hyperplasia and ECLomas also in humans (Solcia 
et al 1990; D'Adda et al 1996). It is known that patients with chronic atrophic gastritis 
have an increased risk of developing gastric carcinoids (Borch et al 1985; Kokkola et 
al 1998). Patients with hypergastrinemia due to sporadic gastrinomas (Zollinger-
Ellison Syndrome (ZES)) without multiple endocrine neoplasia type 1 (MEN1) may 
also develop advanced ECL cell changes and dysplasia (Peghini et al 2002) as well as 
carcinoids (Cadiot et al 1995). Gastric adenocarcinomas have also been associated 
with hypergastrinemia (Rakic et al 1991). 
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6 Gene expression analysis 
6.1 A new era in biomedical research 
The sequencing of the complete human genome (International Human Genome 
Sequencing Consortium 2001; Venter et al 2001) has led us into a new era in 
biomedical research. The post-genomic challenge is to move from genomic sequence 
to a complete understanding of gene function and complex biological processes. 
Increasingly, research in the life sciences is moving from a gene-by-gene approach to 
a Systems Biology approach (Kitano 2002b), essentially driven by a push-pull 
mechanism: the capability to generate high-throughput data for data-driven hypothesis 
generation, and the growing need to understand the dynamic behaviour of biological 
systems. ”Systems Biology” approaches, a novel paradigm for modelling of systems 
function, will for a large part hinge on the availability of robust technology for data 
production.  
Several methods have been developed to be able to meet the growing need for high-
throughput analysis. The microarray technology is a rapidly advancing field gaining 
popularity in many biological diciplines. The technology allows simultaneous 
measurement of the expression of thousands of genes from a single sample, providing 
us with an enormous amount of information compared with more traditional studies of 
single genes. Microarray analysis is a particularly useful tool in cancer research based 
on the complexity of the disease, where many genes and mechanisms are involved 
(Kitano 2004). The cDNA microarray was pioneered by Patric Brown and David 
Botstein (Schena et al 1995), while Affymetrix developed the GeneChip arrays (oligo 
arrays) (Chee et al 1996).  
Other techniques, like serial analysis of gene expression (SAGE) (Velculescu et al 
1995), were also developed to study high throughput gene expression at RNA level. 
However, the microarray methods now seem to be dominating. Microarray-based 
functional genomics technology is a key component of a ”Systems Biology” approach 
for biological function discovery. 
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In addition to sequence information, knowledge of gene function and how gene 
expression modulates cellular phenotype and response to the environment is important 
for understanding tumour biology, the improvement of diagnosis and general 
management of cancer. Variation in gene expression reflects biological function of 
physiological and patophysiological samples, and the use of microarrays to study 
expression patterns in tumours offers a systematic and detailed way of exploring such 
complex biological systems. An advantage of microarray is that it is a translational 
tool that incorporates functional interactions in an attempt to understand biology, not 
simply to identify the component parts of a pathway (Lockhart & Winzeler 2000). 
The ability of cataloguing and classifying genes with characteristic patterns of 
expression in several model systems as well as human cells gives insight into which 
regulatory systems are operative and provides clues to the function of unknown genes 
(Hvidsten et al 2001; Lægreid et al 2003).   
6.2 DNA microarray 
PCR-amplified cDNA sequences or presynthesised oligonucleotide sequences can be  
printed on the array with the aid of a robotic arm, or alternatively oligonucleotide 
sequences may be synthesised directly on the array (e.g. Affymetrix, Rosetta 
Biosoftware/Agilent Technologies). A ”one sample, one array” approach is applied in 
single colour platforms such as Affymetrix and Applied Biosystems Expression Array 
System (ABI). In two-colour platforms, two different fluorophore labels are used. The 
DNA microarray methods are based on complementary base paring, and only spots 
with hybridised sample will have a quantitative signal. In the single colour systems 
test and control samples are hybridised separately to two different microarrays with 
subsequent comparison of signals. In a two-colour-based method there is a 
competitive binding of reference and sample, and the ratio between these two signals 
for each spot are calculated and used for further analysis.  
The different steps in a two-colour experiment will be outlined in the following 
(Figure 3). Total RNA or mRNA is isolated from properly preserved tissue or cell 
samples (snap frozen or RNAlater®). If the sample is limited in size, RNA 
amplification may be necessary to obtain the amount of material needed for the  
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Errors in the IMAGE collections of clones used on cDNA printed microarrays have 
been reported, and additional errors may have occurred during production. For this 
reason, clones representing genes of particular interest, should be sequence verified. 
Duplicate spots and external spike controls printed on the arrays are important issues 
for technical validation. Parameters like input and output ratios, signal linearity, 
hybridisation specificity and consistency across an array can be evaluated by the 
utilisation of exogenous control genes. Moreover, replicate hybridisations can also be 
quite useful as a means of identifying problematic hybridisations in a study, where the 
correlation coefficient between replicates can provide a means of assaying relative 
quality of the arrays. Replicate experiments should also include multiple ”biological 
repeats”. Biological repeats show a higher degree of variability in comparison to mere 
technical replicates of one biological sample but are essential to assess biological 
variation, for statistical analysis and for the generalisation of conclusions. In two-
colour platforms, exchange of the dyes between the experiment and the reference 
sample (a so-called ”dye-swap” experiment) provides additional control of labeling 
and other biases. Microarray observations which are important for the scientific 
interpretation will usually be verified by an alternative method such as Northern Blot, 
dot blot methods, real-time quantitative RT-PCR , Western blot or 
immunohistochemistry (Chuaqui et al 2002; Yadetie et al 2004). 
Translation of individual mRNA species into their encoded proteins is regulated at 
multiple levels: transcriptional control, RNA processing control, RNA transport 
control, translational control, mRNA degradation control and protein activity control 
(Figure 4), producing discrepancies between mRNA and protein levels. As mRNA is 
eventually translated into protein, one might assume that there should be some sort of 
correlation between the level of mRNA and that of protein. Attempts to correlate 
protein abundance with mRNA expression levels have had variable success 
(Greenbaum et al 2003). Some studies found a positive correlation, ranging from  
r = 0.48-0.76 (Anderson & Seilhamer 1997; Futcher et al 1999; Ideker et al 2001). 
Other studies show no significant correlation (Greenbaum et al 2003). However, 
correlations have been found between the mRNA expression levels of different 
protein subunits within protein complexes (Jansen et al 2002). This implies that there 
should be, in general, a correlation between mRNA and protein abundance, as the 
subunits provide a special case as they have to be available in stoichiometric amounts 
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 Figure 4: Six steps at which eucaryote gene expression can be controlled (Alberts et al 1994). 
of proteins for the complexes to function. Thus, a major limitation to find correlation 
is belived to be due to experimental challenges, such as technological limitations in 
mRNA and protein expression experiments (Greenbaum et al 2003). In addition, the 
measurements of mRNA and protein abundance were in some experiments not carried 
out using identical samples, and typically only a small set of protein abundance data 
was used in the analysis. The comparisons will probably become more informative, as 
relatively large datasets of mRNA and proteomic measurements are obtained from the 
same cell samples (Nie et al 2006).  
Observations underscore that analysis at the transcript level, albeit important, is 
insufficient by itself to describe completely the phenotype of cells under different 
conditions (MacKay et al 2004). However, the quantification of protein abundance 
and mRNA expression is not an exercise in redundancy; measurements taken from 
both of these molecular populations are necessary for a complete understanding of 
how the cell works (Hatzimanikatis et al 1999). High-throughput protein 
identification and quantification still lags behind the high-throughput experimental 
techniques used to determine mRNA expression levels as the proteomic arrays are 
still struggling with technical problems. 
6.3 Knowledge discovery 
Typical array experiments create hundreds of thousands of data points in 
highdimensional space defined by the number of samples analysed. This represents a 
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Unsupervised methods are suitable for class and pattern discovery, but they are 
dependent on several parameter settings such as distance matrices, clustering methods 
and types of inter cluster distances which may give rise to a wide range of 
qualitatively different clusters/patterns observed. Presently there is no universal 
standard for how the data analysis should be done, and often the researcher is left to 
explore the different methods and different databases before deciding on a preferred 
approach, whithout really being able to apply stringent, preconceived criteria for the 
choice.  
Biological background information such as gene networks, gene pathways and gene 
ontology are partly available through public databases. An increasing number of 
companies and academic institutions are further developing the technique, making 
complete packages consisting of e.g. statistical tools, ontology and pathway analysis 
(microarray analysis reviewed in; (Wildsmith & Elcock 2001; Stears et al 2003)). 
6.4 Molecular profiling  
Breast cancer was among the first malignant diseases subjected to large-scale gene 
expression analysis. Breast cancer is a complex disease, with large variability between 
breast cancer patients regarding prognosis and treatment response. A search for 
predictive and prognostic markers has been going on for a long time and clinical 
markers in present use are variables like age, lymph node status, receptor status, 
proto-oncogenes, and gene mutations. However, these methods need further 
refinement and breast cancer was an obvious choice when the first large-scale gene 
expression analyses of solid malignant tumours were done. Several laboratories have 
reported that unsupervised clustering of microarray-generated gene expression data 
from breast cancer consistently separates estrogen receptor positive and negative 
tumours into two clusters (Perou et al 2000; Gruvberger et al 2001), strongly 
suggesting that genomewide expression analysis can indeed identify clinically 
important disease subclasses and discover new subclasses (Sørlie et al 2001). 
Moreover, the supervised methods applied by Hedenfalk et al could distinguish 
sporadic breast cancer from breast cancer, early onset (BRCA) mutant cases 
(Hedenfalk et al 2001). Most interesting, studies using supervised learning have 
demonstrated that microarray analysis can predict overall and relapse-free survival 
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based on "predictive gene sets" that are superior to currently available clinical and 
histologic prognostic models (van de Vijver et al 2002; van't Veer et al 2002; Lossos 
et al 2004). 
The application of unsupervised methods to diseases such as nonsmall cell lung 
cancer, lymphoma, oesophageal carcinoma, and Barrett's oesophagus have similarly 
shown the use of microarray in documenting tumour subgroups that correlate with 
clinicopathological parameters and survival (Alizadeh et al 2000; Wigle et al 2002; 
Selaru et al 2002). On the other hand, supervised methods have e.g. been applied to 
predict recurrence rates for hepatocellular carcinoma (Iizuka et al 2003), and to 
classify and predict leukemia subtypes, drug resistance and treatment outcome (Golub 
et al 1999; Yeoh et al 2002; Holleman et al 2004). 
Although most microarray analysis on disease states has concentrated on 
malignancies, the method is increasingly being utilised in studies also on other 
diseases. Subgroups of patients with glomerulonephritis (Peterson et al 2004) have 
been identified by means of unsupervised learning. In patients with heart failure, gene 
expression profiling combined with supervised learning could predict cardiomyopathy 
etiology (Kittleson et al 2004). Microarray profiling and significance analysis have 
been applied as tools to provide better understanding of nonalcoholic steatohepatitis 
(Sreekumar et al 2003) and autoimmune diseases (Qing & Putterman 2004; Jarvis et 
al 2004). 
In addition to exploring disease, genome profiling has been applied to study normal 
physiological processes in humans and several model systems. Microarrays 
containing virtually all yeast genes have been used to study coregulated genes linked 
to a variety of conditions as differences in metabolic state (DeRisi et al 1997), growth 
conditions (Wodicka et al 1997), sporulation (Chu et al 1998) and cell cycle 
regulation (Spellman et al 1998), by use of clustering algorithms (unsupervised 
learning). In vivo effects of growth hormone have been studied in liver, heart and 
kidney of rats (Flores-Morales et al 2001; Tollet-Egnell et al 2001). In these studies, 
differentially expressed genes and involved biological processes were identified. 
There have been several reports on the use of microarrays to study expression patterns 
in cultivated human cells under different experimental conditions, for example heat 
shock responses in T-cells (significance analysis) (Schena et al 1996), and the 
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response to fibroblast serum stimulation (clustering of genes) (Iyer et al 1999). de 
Veer et al compiled data from many experiments on human and murine cell lines, 
using two different microarray formats to obtain a more comprehensive list and a 
better understanding of genes regulated by interferons (de Veer et al 2001). 
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Aims of the studies 
• to characterise NE features of AR42J cells and elucidate whether this cell line can 
be used as a model system for NE tumours (I) 
• to establish microarray methods for small amounts of biological material (II) 
• to establish methods for data analysis and supervised learning/classification, and 
develop classifiers for gastric carcinoma with respect to several clinical 
parameters (II) 
• to examine the effects of potent acid inhibition (proton pump inhibitor, PPI) on 
genome-wide gene expression in rats, on biological process and single gene levels 
(III) 
• to investigate the effects of therapeutic doses of a potent acid inhibitor (proton 
pump inhibitor, PPI) on genome-wide gene expression in patients, on biological 
process and single gene levels (IV) 
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Summary of papers 
Paper I:  
Expression of chromogranin A and  somatostatin receptors in pancreatic AR42J cells. 
In this paper, some NE features of the rat pancreatic acinar cell line AR42J were 
studied. The results show that AR42J cells express CgA mRNA, and secrete its 
cleavage product pancreastatin. Gene expression of CgA was upregulated by gastrin 
and EGF. Some of  the cells have NE secretion granules and are faintly 
immunoreactive to NE markers, indicating that the cells are of  a rather poorly 
differentiated type. AR42J cells express SSTR subtype 1, 2, 3 and 5. Proliferation 
studies showed that the SST analog octreotide inhibits gastrin-induced proliferation, 
confirming the expression of functional SSTR in AR42J. The results suggest that 
AR42J cell line could be a useful experimental model to study the regulation of CgA 
and SSTRs. 
Paper II: 
Gene expression based classification of gastric carcinoma.  
Gastric carcinoma is the second most frequent cause of cancer death world-wide. 
Using cDNA microarray analysis with a 2504 gene probe set, we have shown in this 
paper that microarray analysis of gastric carcinoma can produce data that are 
significantly related to important clinicopathological features. Using a supervised 
learning method, we were able to generate reliable classifiers for prediction of several 
clinically important parameters, including histopathological classification (Laurén), 
presence of lymph node metastasis and location of tumour. Our work also identified 
several genes that were not previously known to display characteristic expression 
patterns in gastric carcinoma. 
Paper III: 
Molecular characterisation of rat gastric mucosal response to potent acid inhibition.  
Inhibitors of gastric acid secretion are among the most commonly used drugs in 
clinical practice. Proton pump inhibitors (PPIs) cause profound changes in the 
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intragastric environment with near-neutral pH, and increase serum concentration of 
the gastric secretagogue hormone gastrin. Long-term hypergastrinemia increases 
mucosal thickness and ECL cell density in gastric corpus mucosa, and results in 
development of gastric carcinoids in experimental animals. The aim of this study was 
to elucidate molecular responses in gastric mucosa of rats receiving the proton pump 
inhibitor omeprazole for 10 weeks by measuring genome-wide transcript level 
changes using cDNA microarrays with probes representing 11848 genes. Our results 
indicate a global change in the induction of proliferation, apoptosis, inflammatory, 
immune and stress response in the presence of proton pump inhibitors. Several of the 
identified genes were previously known to be affected by potent acid inhibition. 
However, many genes were identified that were not previously known to respond to 
inhibition of gastric acid secretion or that have unknown biological functions. 
Characterisation of the roles of these genes may give new insight into molecular 
responses to treatment with PPIs.  
Paper IV: 
Changes in gene expression of gastric mucosa during therapeutic acid inhibition.  
Knowledge of the effect on mucosal gene expression of PPIs given to humans in 
ordinary, therapeutic doses is limited. Eight patients suffering from gastro-
oesophageal reflux disease were included in this study. Endoscopic biopsies were 
taken from the corpus mucosa before and towards the end of a three-month treatment 
period with the PPI esomeprazole. Using cDNA microarrays with probes representing 
5346 genes, a large set of candidate genes not previously associated with acid 
inhibition was identified, which underlining the complex molecular responses to this 
therapeutic intervention. Our results indicate a global change in the induction of the 
same biological processes as identified in paper III. Moreover, eight genes were found 
to be regulated in the same direction in rats and patients in response PPIs. The genes 
presented in this study are likely to be associated with acid inhibition. Further studies 
specifically targeting the genes implicated in this study will further our understanding 
of the molecular responses to potent acid inhibition, including the mucosal response to 
moderately increased gastrin levels encountered in clinical practice. 
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General discussion 
7 Methodological considerations 
DNA microarray analysis is the main method used in the present study. Thus, only 
microarray will be considered in this chapter. For all other methods used, standard 
procedures were performed.  
The four studies presented in this thesis reflect the development in technology that has 
taken place over the last few years, from studies focusing on single gene analysis to 
whole genome studies. As the techniques are constantly developing, new variants of 
the methods were used for each paper. The milestone of sequencing the human 
genome was achieved during this period (International Human Genome Sequencing 
Consortium 2001; Venter et al 2001), and a whole new world of knowledge has 
become available through the enormous increase in available bioinformatics tools. 
7.1 cDNA microarrays   
Only cDNA microarrays were available when the present studies were performed. 
Thus, glass microarrays with cDNA clones (200-2000 nucleotides in length) printed 
by the Norwegian Microarray Consortium, were used in the studies presented in this 
thesis. The cDNA clones spotted on the arrays were from publicly available clones 
obtained from the IMAGE consortium (Lennon et al 1996) and some clones were 
generated in-house for our specific areas of interest. Errors in the IMAGE collections 
of clones have been reported, and additional errors may have occurred during 
production. For this reason, in paper III and IV, clones representing genes of 
particular interest were sequence verified.  
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One of the major concerns of cDNA microarrays is cross-hybridisation of the labeled 
RNA (or cDNA) to non-target homologous probe sequences on the array (Evertsz et 
al 2001; Afshari 2002). Due to poly(A)-tail of mRNA, PCR-products (cDNAs) 
contain poly (dA/dT) sequences. Cross-hybridisation and non-specific hybridisations 
that arise due to poly (dA/dT) sequences or repetitive elements were reduced or 
eliminated using blocking reagents like cot-1 and LNA dT blocker. Generally, only 
a minimal background noise from the array can be accepted, and small variations in 
production of arrays and experimental conditions can create immense background 
staining. Moreover, the uneven length of the cDNA printed on the arrays makes it 
difficult to find an optimal hybridisation temperature. As cross-hybridisation is known 
to be one of the main sources of errors in cDNA microarrays, particularly interesting 
results from the microarray experiments in paper II and III were validated using RT-
PCR or Northern blot analysis, respectively. The long length of the cDNA probe 
makes hybridisation more stable compared to oligo probes, allowing the use of more 
stringent washing conditions in order to reduce noise signal. 
Oligonucleotides offer greater specificity than cDNAs or PCR products, having the 
capacity to distinguish single-nucleotide polymorphisms and discern splice variants. 
Compared with the cDNA probes, a smaller percentage of the oligonucleotide probes 
show a potential for cross-hybridisation (Flikka et al 2004). This is because the 
oligonucleotide probe sequences are much shorter (60-70 nucleotides), designed from 
specific regions of cDNA to minimise cross-hybridisations. However, conserved gene 
sequences coding for functionally related proteins could be sufficiently long to cross-
hybridise in arrays using shorter oligos (Hughes et al 2001). For oligo nucleotide 
arrays, quality control for the immobilised sequence is done during syntesis, making it 
unnecessary to perform sequence verification. Also, the fact that the production of 
oligonucleotide microarrays does not require handling of a large clone collection 
reduces the need of a costly infrastructure. 
7.2 3DNA labeling method 
In the present study we used a microarray labeling and hybridisation protocol  
(Figure 6) that enables the use of very small amounts of RNA without amplification 
(Stears et al 2000). The 3DNA labeling system provides a more predictable and 
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consistent signal than direct or indirect dye incorporation for two reasons. First, since 
the fluorescent dye is part of the 3DNA dendrimer reagent, it does not have to be 
incorporated during the cDNA preparation. This avoids the ineffective cDNA 
synthesis observed when direct incorporation methods are used. Direct incorporation 
also generates a risk of unequal incorporation of Cy3 and Cy5 labeled nucleotides and 
dye-specific hybridisation artefacts. Second, because each 3DNA molecule contains 
an average of about 375 fluorescent dyes and each bound cDNA will be detected by a 
single 3DNA molecule, the signal generated from each message will be largely 
independent of base composition or length of the transcript. In contrast, the signal 
generated from each message labeled through direct dye incorporation will vary 
depending on the base composition and length of the message. 
A narrow window of change of expression is observed in most of our microarray 
analyses. This appears to be a result of low dynamic range of fluorescent signals 
obtained using the dendrimer labeling and hybridisation protocol, compared with 
other labeling methods (unpublished results from our laboratory). This has been 
confirmed in studies comparing the dendrimer labeling method with other labeling 
methods, concluding that the dendrimer method has a lower dynamic range 
(Manduchi et al 2002; Richter et al 2002). Despite these limitations, the method can 
identify differentially regulated genes with reasonable accuracy, as we show using 
Northern blotting and spiked external controls. However, efforts were made to limit 
the compression effect in the present study, as Genisphere has provided improved 
protocols. A new reagent, the “high-end differential enhancer” addressed a portion of 
the compressed differentials. The “high-end differential enhancer” block the unlabled 
arms (meaning arms that did not receive eighter a fluorescent dye labeled oligo or a 
complementary sequence oligo to the primer). Another blocking reagent, the Locked 
Nucleic Acid blockers (LNA dT Blocker), was also added to the kit. PCR-products 
(cDNAs) contain poly (dA/dT) sequences. The LNA dT Blocker is a high-
performance poly T based blocking reagent designed to completely block all the poly 
dA sequences present in the cDNA probes (Singh et al 1998). A regular oligo dT 
blocker, which we initially used, have an on-off interaction. The LNA dT blocker, 
once they hybridise on to a string of A’s it is locked, so it is able to completely block 
all poly dA spots. In addition, a “two-step” hybridisation  protocol was introduced, 
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Figure 6: Outline of the different steps in a "two-step" microarray detection protocol with 
3DNA reagent. Alternatively, a "one step protocol" can be applied, in which the cDNA is pre-
hybridised to the fluorescent 3DNA to produce a cDNA/3DNA complex with subsequent 
hybridisation of the complex to the array (Genisphere). 
adding the bulky 3DNA fluorescent probe after cDNA hybridisation, and thus 
circumventing any sterical hindrance during hybridisation. In the previous “one-step 
protocol”, the cDNA is pre-hybridised to the fluorescent 3DNA to produce a 
cDNA/3DNA complex with subsequent hybridisation of the complex to the array. The 
two-step hybridisation improves the signal intensities and the dynamic range, mainly 
for low level expressors. The one-step protocol was used in paper II. In paper IV, the 
one-step protocol and the “high-end differential enhancer” were used. In paper III, the 
two-step protocol, the “high-end differential enhancer” and LNA dT Blocker were 
applied. 
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7.3 Quality control 
7.3.1 Spike-in controls 
In general, microarrays pose tremendous challenges to the user, and the technology is 
still struggling to achieve good quality standards. The commercial SpotReport Array 
Validation System (Stratagene) (spike-in controls) was used in paper III and IV for 
assessment of experimental performance. The spike-in controls consist of exogenous 
RNA transcripts, which were added to the RNA samples prior to reverse transcription 
and labeling. The arrays were spotted with probes for these exogenous transcripts. 
Different amounts of each exogenous transcript was added to the test and reference 
samples to generate pre-determined signal ratios between fluorescent dyes upon 
scanning of the array. This information was used to evaluate reverse transcription and 
labeling procedures, as well as for assessing the dynamic range of the assay.  
Labeled reverse complementary oligonucleotides offer another candidate for reference 
sample purposes. Oligonucleotides are stable, easy to quality control and quantify, can 
be designed to contain specific sequences and can produce consistent signals across 
arrays. Such controls can be used to monitor the hybridisation step in a very 
controlled manner. 
7.3.2 Replicates 
Due to cost and low amount of sample material (paper II and IV), technical replicates 
such as repeated hybridisations and dye-swaps were not performed. Compared with 
direct incorporation of labeled nucleotides, the 3DNA method enables a more even 
hybridisation of the two dyes. For this reasons, dye-swap replicates were regarded as 
less important, and hence not included. Labeling has caused debate the past couple of 
years, as one of the fluorescent colours (Cy5) used worldwide seemed to bleach very 
fast, and finally ozone was suggested to cause this problem (Fare et al 2003). 
Artefacts due to different sensitivity to photobleaching could have been monitored 
better if dye-swaps had been included. However, the normalisation process can 
balance many of the systematic variations. Each individual clone was replicated two 
or more times at different locations of the array. With this layout, random and 
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systematic measurement errors in the microarray process that might affect the data 
can be easily assessed, and more reliable information can be gained from a single 
experiment. As a consequence, the number of hybridisation experiments can be 
reduced. Several biological replicates were included in the present microarray papers.  
In the present study, all hybridisations were performed manually. Today, to ensure a 
more even and reproduceable hybridisation and subsequent washing procedure, and 
reduce the "hands on" time, the use of a hybridisation station is preferable. 
7.3.3 Universal reference samples 
In paper II, universal human reference RNA obtained from Strategene was used to 
generate a reproducible hybridisation control over a series of arrays, thus providing a 
base level against which the relative abundance of transcripts from test samples can be 
measured. Pooled RNA from cell lines were used as a universal reference sample. 
Cell lines provide an abundant source of RNA, and a mixture of RNA from several 
cells is used for production of several commercially available universal reference 
RNAs. There is an ongoing effort to standardise the reference material 
(Novoradovskaya et al 2004; Cronin et al 2004). The ability to perform comparisons 
between experiments, platforms and laboratories can be greatly enhanced if all users 
incorporate such a standard into their process. Concerns over this approach, however, 
have been raised as the pooling of RNA from several cell lines may result in some 
low abundance transcripts being diluted below the limit of detection.  
From a standardisation point of view, the use of this cellular RNA is sub-optimal for 
several reasons: 1) the relative expression of transcripts within and between cell lines 
is not necessarily stable over time and may result in batch-to-batch variation; 2) the 
application of a primary RNA standard against which rigorous quality control can be 
performed is challenging due to the unstable nature of the raw material; 3) the 
inadequate reliability when measuring absolute quantities of each individual transcript 
within the reference sample makes sample characterisation a challenge; 4) the 
statistics behind the indirect comparison method utilising a common reference are less 
favourable than that of direct methods, due to an elevated variation (four-fold). 
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 However, although the material may be sub-optimal, it may still help in the pursuit of 
array standardisation as no better universally accepted standards are currently 
available. Several other materials can be used as a reference, such as a mixture of 
cDNA products spotted onto arrays, a mix of labeled oligos complementary to every 
microarray probe or genomic DNA (Novoradovskaya et al 2004). 
8 Results and discussion 
In the last few years several lines of evidence have emerged which suggest that the 
biology of gastrin is much more complicated than indicated by earlier works. In 
particular, studies of (1) the various peptides generated during gastrin biosyntesis, (2) 
genetically modified mice that overexpress the gastrin gene or in which the genes 
encoding gastrin or its receptor have been deleted, (3) the phenotype of patients with 
hypergastrinemia, and (4) new targets indicated by functional genomic methods (gene 
arrays and proteomics) all indicate that gastrin, and possibly its variants, are 
implicated in a wide variety of biological processes, including effects outside the 
stomach. We have only a limited knowledge of molecular mechanisms involved in the 
complex physiological and pathophysiological responses to gastrin. There is abundant 
evidence to suggest that gastrin may play an important role in tumour biology 
(Dockray et al 2005). Hypergastrinemia is associated with the occurrence of gastric 
ECL cell carcinoid tumours and with an increased risk of gastric carcinoma (Dockray 
et al 2005). The present work examines some aspects of the biology of the gastrin-
responsive cell line AR42J, molecular responses to acid inhibition in gastric mucosa, 
and gene expression based classification of gastric carcinoma. 
8.1 Molecular profiling of gastric carcinoma 
To produce a metastasis, tumour cells must complete a multistep progression through 
a series of sequential and selective events. The metastatic process consists of tumour 
cell detachment, local invasion, motility, angiogenesis, vessel invasion, survival in the 
circulation, adhesion to endothelial cells, extravasation, and regrowth in different 
organs. In each step, causative molecules have been identified, including cell-
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adhesion molecules, various growth factors, matrix degradation enzymes, and motility 
factors, and most of these can be regarded as prognostic factors since they are related 
to local and distant dissemination of tumour. A recent study aimed to identify 
metastasis related genes in gastric cancer comparing cell lines from low and highly 
metastatic gastric cancer, using an unsupervised clustering method (Fukui et al 2005). 
However, cluster analysis is a very subjective analysis strategy. In paper II, we instead 
used a supervised learning method to develop classifiers for several steps in the 
metastatic process; penetration of gastric wall, lymph node metastasis and remote 
metastasis. Not surprising, these classifiers include genes like cadherins, integrins and 
laminin binding genes. In addition, several novel metastasis-related genes were 
identified that might give indications on how to uncover the precise mechanisms of 
the development and progression of gastric carcinoma.   
The majority of microarray studies examining gastric adenocarcinoma have been 
aimed at developing exploratory gene profiles of gastric tumour or gastric cancer cell 
lines to identify gastric cancer-related genes, delineate molecular phenotypes, 
demonstrate tumour subclasses, and identify functional gene clusters as potential 
markers of biologic behavior, using unsupervised learning methods (El-Rifai et al 
2001; Hippo et al 2001; Lee et al 2002; Hippo et al 2002; Liu et al 2002; Ji et al 
2002; Meireles et al 2003; Yu et al 2005). Results by Wu et al and Boussioutas et al 
indicate that Lauréns classification reflects significant molecular differences in gastric 
carcinomas (Boussioutas et al 2003; Wu et al 2006). However, these studies did not 
apply supervised methods to create classifiers. Like our results in paper II, modeling 
for prediction of diffuse type and intestinal type of gastric cancers using a supervised 
method, identified genes that may represent distinct molecular signatures of each 
histological type (Jinawath et al 2004). Recent studies have shown that microarray, 
using supervised methods in combination with statistical modeling, accurately 
predicted tumour behavior with respect to tumour progression, metastatic potential, 
tumour recurrence, and overall prognosis/survival (Inoue et al 2002; Hasegawa et al 
2002; Meireles et al 2004; Chen et al 2005). However, to my knowledge, paper II is 
still the only study on gastric carcinoma in which molecular classification has been 
achieved for several clinicopathological parameters based on microarray gene 
expression profiles. Although in its infancy, gene expression analysis, combined with 
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predictive models, holds promise in extending our understanding and possibly 
improving classification and treatment of gastric carcinoma. 
8.2 Heterogenous tissue 
In paper II, III and IV, tissue biopsies were used. When assaying a tissue sample, the 
microarray result reflects the sum of gene expression in all cell types in the sample. 
There has been some concern around the question of the heterogenity of solid tissue. 
Some researchers have tried to approach the problem by methods like laser 
microdissection of tumour material before mRNA is extracted (Klur et al 2004; 
Mizuarai et al 2005). One should bear in mind, however, that the disease process 
often is the result of interaction between the pathological cells themselves and 
surrounding stroma, like for instance in the processes of invasion, metastasis and 
angiogenesis. Thus, analysis of the gene expression in the whole tissue may actually 
in some instances be more informative than examination of only the distinctly 
pathological cells (Nakagawa et al 2004). In the case of solid tumours as those which 
are used as a source of RNA in paper II, the tissue is composed not only of tumour 
cells but also comes together with normal cells, stromal cells, infiltrating 
inflammatory cells, endothelial cells, etc. This heterogenity does interfere with gene 
expression profile but one could argue that the biology of the tumour is a result of the 
interaction of these various cell types and hence, it could be relevant to have them all 
in the sample under examination. Moreover, one study indicates a low degree of 
expression profile variability within gastric tumour samples isolated from one gastric 
cancer patient. Those data suggest that tumour tissue heterogenity is not a dominant 
source of error for microarray analysis of large tumour samples, making total RNA 
extraction an appropriate strategy for performing gene ship expression profiling of 
gastric cancer (Trautmann et al 2005). 
A possible complication by a whole tissue approach is if different cell types regulate 
the same genes in opposite directions. If a gene is up-regulated in one cell type and 
down-regulated in another, the overall sum of gene expression may cancel out giving 
the impression of not being important. Further studies are needed to clarify this aspect 
of gene expression measurement in complex systems. 
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Interestingly, as shown in paper III, gene-expression arrays can indeed provide a 
sensitive measure of gene changes within a minor subpopulation of cells, as the 
increased gene expression of the ECL cell-specific genes HDC and Reg was clearly 
observable, even though the ECL cells only comprise about 1% of the total cell mass 
in the rat gastric mucosa. Another study has found that microarrays can detect gene 
expression in merely 5% of the total cell population (Hamadeh et al 2002). These 
findings indicate that, if a cell culture or tissue is heterogenous, significant changes 
may be related to only a small fraction of the cells; and investigators may wish to 
confirm localisation with a microscopic technique, as we did for some gene products 
in paper III and IV. 
8.3 PPI-induced acid inhibition 
The consequences of profound and sustained PPI-induced acid inhibition have been 
carefully evaluated in a number of recent reports; (Lamberts et al 1988; Solcia et al 
1989; Lamberts et al 1993; Solcia et al 1993). Such studies have, as yet, revealed no 
irreversible pathological changes directly related to ECL cell neoplasia in patients 
with longterm hypergastrinemia. However, treatment with PPIs increases fasting 
serum gastrin about 2-3 fold after 1 month (Genta et al 2003) or 3 months (Eissele et 
al 1997), and very high gastrin levels are seen in 10% of the patients (Klinkenberg-
Knol et al 1994; Eissele et al 1997). Furthermore, multiple measurements of serum 
gastrin in patients undergoing similar treatment as described in paper IV, showed that 
the 24-h gastrin exposure is far higher during PPI treatment than is reflected by a 
single fasting gastrin measurement (Waldum et al 1996a). Thus, the gastrin exposure 
of the gastric mucosa in paper IV is much more pronounced than suggested by the 
relatively modest increase in fasting serum gastrin. A clear quantification of what is 
an unsafe exposure to gastrin has not yet been established, but the maximal trophic 
effect of gastrin is reached at levels lower than previously realised (200-500 pM) 
(Sjöblom et al 1991; Brenna & Waldum 1992). Provided long-term hypergastrinemia, 
it seems that all conditions with hypergastrinemia are associated with ECL cell 
hyperplasia, dysplasia or neoplasia and some researchers have warned against long-
term inhibition of gastric acid secretion since the mid 1980s.  
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In paper IV, changes of gene expression in human gastric oxyntic mucosa were 
studied in patients receiving a therapeutic dose of the PPI esomeprazole. These were 
studied after a treatment period of three months. Interestingly, the treatment induced 
significant changes in the gene expression of a high number of genes. A higher dose 
of PPI and a relatively longer dosage period (compared with lifetime) were used in the 
corresponding rat study (paper III). In addition, different microarrays, representing 
different genes, were used. Thus, it is not surprising that few common genes were 
found to be differentially expressed in both rats and patients. However, a number of 
genes were indeed regulated in the same direction in both studies. These genes are 
considered highly relevant to the molecular responses to potent acid inhibition. Also, 
the endocrine-specific protein-18 (RESP18), which is upregulated in response to PPI 
in rats, is an interesting candidate gene for further analysis. RESP18 has lately been 
shown to be upregulated in hypergastrinemic rodent mastomys (Kidd et al 2004). 
Further characterisation of the functional roles of these genes may give new insight 
into the biological responses to this very common therapeutic intervention.  
Moreover, looking at the PPI responses at a biological process level, using Gene 
Ontology (GO), similar results were observed in the two studies. GO provides 
information by structuring biological knowledge with a controlled vocabulary 
consisting of GO terms, that enable us to understand the molecular picture better. Of 
the differentially expressed genes with known function, 40% and 34% are involved in 
the biological processes proliferation and/or apoptosis in PPI-dosed patients and rats, 
respectively. The corresponding numbers of genes involved in stress and 
inflammatory/immune responses are 21% and 22%, respectively. The fraction of 
genes involved in these processes was remarkably similar for rats and patients. Other 
studies also show that comparable biological themes emerge from data across 
disparate platforms and laboratories when GO nodes are used to analyse collections of 
genes representative of biological themes instead of direct gene-by-gene comparisons 
(Segal et al 2004; Bammler et al 2005). A recent study showed that the biological 
representations such as those expressed in GO classifications of the genes are more 
important to understand molecular mechanisms than the genes themselves (Bammler 
et al 2005). Even if on a gene-by-gene basis they found inconsistency, when they 
looked at the processes themselves, the conserved prosesses represented by regulated 
genes were there. Looking at the level of the biological process annotation rather than 
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the gene gives a more biologically meaningful and statistically robust approach to 
data analysis (Petersen et al 2005).  
The final outcome of human ECL cell hyperplasia in prolonged low-acid states awaits 
full characterisation. Only long-term studies can elucidate the consequences on the 
ECL cell system of potent acid-suppressive pharmacotherapy and elevated gastrin 
levels. Although the putative malignant potential of gastric carcinoids may ultimately 
be of only modest concern in a background of hypergastrinemia, its relationship to 
gastric adenocarcinoma is still enigmatic and worthy of further consideration. 
Valuable insights into the regulation of gastric mucosal turnover will undoubtedly be 
gained from continued study of the biology of this gastrin-generated neoplasm of the 
gastric mucosa. The results in paper III and IV may contribute to new insight into the 
biological responses to treatment with PPIs, both on biological process and single 
gene levels. 
8.4 AR42J as a cell model system 
To understand the molecular mechanisms governing normal physiological processes 
and oncogenesis is an essential first step in the design of effective therapies. Research 
into the molecular mechanisms underlying the various aspects of physiology and 
patophysiology requires the use of in vivo and in vitro model systems. Animal models 
are often beneficial in this regard, but present significant drawbacks, including ethical 
concerns and the lack of appropriate models for the mechanism being studied. 
Moreover, to elucidate spesific mechanisms, simplified model systems are necessary. 
Thus, cell culture models have been developed that mimic various physiological 
conditions and cancer types.  
Reports show that gastrin is a major trophic factor for several neoplastic cell types, 
including the pancreatic acinar cell derived cell line AR42J (Seva et al 1994), which 
we characterise with respect to NE features in paper I. The CCK-2 receptor belongs to 
the seven-transmembrane domain, G-protein coupled, receptor superfamily. This 
receptor has been shown to be expressed in several GI and pancreatic tumour cell 
lines, including AR42J (Watson et al 1998). It is normally coupled to Gαq/11 and 
activation leads to an increase in intracellular Ca2+ and protein kinase C (PKC). The 
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mechanisms have been studied in parietal cells and ECL cells (Sachs et al 1997; 
Kinoshita et al 1998). In addition, there is a considerable volume of work on 
signalling via CCK-2 receptors in other CCK-2 receptor-expressing tissues, like 
pituitary, pancreatic islets and cancer cell lines. The data indicate activation of the 
mitogen activated protein kinase (MAPK), phospholipase C (PLC) and 
phosphoinositide 3-kinase (PI3-K)/Akt signalling pathways (rewieved in (Todisco 
2000)). Thus, it is clear that gastrin activates growth signaling pathways. 
Gastrin is known to play a pivotal role in the regulation of genes containing cAMP 
responsive elements (CRE), including the CgA and somatostatin genes (Montminy & 
Bilezikjian 1987; Wu et al 1995). Proteins binding to this sequence (CREB) are 
activated by increase in intracellular cAMP. Todisco et al. (Todisco et al 1997) 
reported that gastrin-mediated proliferation in AR42J probably involves both PKC-
dependent and PKC-independent mechanisms. Studies on this cell line show that 
gastrin-mediated proliferation also involves PKA, identified CRE as a gastrin 
responsive promotor element and found that CRE is indispensible for gastrin-induced 
activation of the c-fos promotor in AR42J (Thommesen et al 2001). We have 
previously shown that gastrin induces expression of the CRE-responsive gene 
inducible cAMP early repressor (ICER), which is suggested to play a role in negative 
feedback regulation of genes activated via CRE (Thommesen et al 2000). Thus CRE 
promoter elements may play a central role in gastrin-mediated modulation of gene 
expression involved in physiological effects of gastrin. 
Gastric cell lines have been widely used as experimental models to study the genetics, 
pharmacology and biochemistry of gastric cancers. A study comparing gene 
expression profiles of 12 gastric adenocarcinoma cell lines to gene expression patterns 
of 15 cell lines derived from other epithelial cancers, found a marked heterogenity 
among the expression patterns of the cell lines with origin from the GI tract (Ji et al 
2002). The heterogenity may reflect the underlying molecular characteristics or 
specific differentiation programs. In another study, gene expression analysis of six 
different gastric cancer cell lines with different metastatic potentials in terms of grade 
and target was examined to clarify the mechanism of gastric peritoneal dessemination 
(Sakakura et al 2002). 
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Moreover, molecular mechanisms underlying proliferative responses to gastrin, HGF, 
EGF and PACAP have been studied by transcript profiling in the carcinoid tumour 
cell line BON (Hofsli et al 2005). By identifying a number of growth factor-
responsive genes in human NE GI tumour cells, useful hypotheses for further studies 
aimed to search for new therapeutic targets as well as tumour markers in NE GI 
tumours were provided.  
AR42J is considered to be an interesting model for the study of a possible 
involvement of ICER in gastrin-mediated cellular responses and signaling 
mechanisms of CCK-2 receptor (Thommesen et al 2000). In paper I, we propose that 
AR42J, showing gastrin-induced proliferation and expressing CgA and several 
SSTRs, also might be a valuable experimental model to study molecular mechanisms 
involved in the biology of NE tumour cells, including the regulation of the NE cell 
marker CgA and SSTRs. 
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Concluding remarks and future perspectives 
The four studies presented aimed to shed light on molecular aspects of gastric 
carcinoma, growth related gene expression of gastric mucosa and the NE cell line 
AR42J. The main conclusions are: 
• AR42J displays several NE features and can be used as a model to study the 
regulation of CgA and SSTRs in response to gastrin. 
• A model for classification of gastric carcinoma with respect to several important 
clinicopathological parameters was developed. 
• The biological processes proliferation, apoptosis, stress, inflammatory and 
immune responses are shown to be affected by potent acid inhibition of gastric 
mucosa in both rats and humans. A large number of genes responding to inhibition 
of gastric acid secretion were identified.  
These studies are an example of how future research in molecular biology may be 
performed, switching back and forth between detailed studies of genes/proteins and 
high-throughput analysis. Development of new technology and characterisation of the 
human genome sequence has made this approach possible, and one of the greatest 
challenges now is within bioinformatics and statistics. Also important is to continue 
building bridges between the different branches of science, to be able to develop the 
emerging field of Systems Biology (Kitano 2002b). 
Several aspects of the findings presented will undergo follow up in future studies. The 
classification model for gastric carcinoma will be extended using a higher number of 
samples. Furthermore, the classifiers developed will be tested using an independent 
“test set” of samples. Moreover, differentially expressed genes in gastric tumours 
compared with gastric mucosa in healthy individuals will be explored in a new study. 
Some of the most interesting genes regulated by PPIs will be studied further to 
elucidate their role in acid secretion and proliferation of gastric mucosa. 
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It is conceivable that endoscopically obtained tissue samples may be used to generate 
preoperative predictive gene clusters. Full scale DNA microarray technology will 
probably be too advanced and laborious to be of any routine use in the clinic. 
However, a qualified assortment of markers elucidated from full-scale DNA 
microarray analysis will have great potential in routine determination of diagnosis and 
prognosis in the clinic. Characterisation of genes that are differentially expressed in 
gastric carcinoma is essential for accurate diagnosis and tumour characterisation and 
for informed surgical and adjuvant therapy decision-making, development of novel 
therapeutics, and delineation of tumour behavior for more accurate prognostication. 
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Abstract
The exocrine pancreatic cell line AR42J is also known to display some neuroendocrine (NE) features. We have extended this fact
by showing that AR42J cells express mRNA of chromogranin A (CgA), display immunoreactivity (IR) to CgA, and secrete its
cleavage product pancreastatin. A sparse occurrence of typical NE secretion granules, together with only a faint IR to conventional
NE markers, indicates that the NE cells are of a poorly differentiated type. CgA promoter reporter plasmid experiments showed that
gastrin, epidermal growth factor, and phorbol 12-myristate 13-acetate, induce upregulation of CgA after 24 h. By RT-PCR, it was
found that AR42J expresses all of the five subtypes of the somatostatin (SST) receptor (SSTR) family, except SSTR4. The existence
of functional SSTRs was confirmed by showing that the SST analog octreotide could inhibit gastrin-induced proliferation. Thus, the
AR42J cell line may function as a valuable experimental model to study the regulation of CgA and SSTRs in poorly differentiated
NE tumor cells. # 2002 Elsevier Science Ireland Ltd. All rights reserved.
Keywords: Pancreastatin; Neuroendocrine features; Somatostatin receptors; AR42J; Reporter-gene
1. Introduction
The rat AR42J cell line is a widely used experimental
model system for studies of pancreatic acinar cells
(Rosewicz et al., 1992; Christophe, 1994). The cell line
derives from a chemically induced pancreatic adenocar-
cinoma (Longnecker et al., 1979). In addition to its well-
known exocrine properties, it also displays some neu-
roendocrine (NE) features such as the expression of the
typical NE vesicle protein synaptophysin (Syn), the
synaptic vesicle protein type 2 (SV2), voltage-activated
ionic channels (Kusano and Gainer, 1991), as well as the
neurotransmitters GABA, glutamate and glycine (Ro-
sewicz et al., 1992; Christophe, 1994). AR42J cells also
express some transcription factors typically found in NE
cells (Palgi et al., 2000). Furthermore, upon treatment
with betacellulin, a member of the epidermal growth
factor family (EGF), or with hepatocyte growth factor,
in combination with activin, AR42J cells differentiate
into insulin-producing cells (Mashima et al., 1996a,b).
This has also been shown after treatment with glucagon-
like peptide 1 and exendin-4 (Zhou et al., 1999). These
observations suggest that this cell line can serve as an
experimental model to study the formation and differ-
entiation of pancreatic endocrine cells.
Chromogranin A (CgA) belongs to the granin family
of acidic secretory glycoproteins that are expressed in
most types of normal NE cells and in the parenchyma of
most NE tumors (c.f. Nobels et al., 1998; Wick, 2000).
CgA is typically bound to the membrane of the NE
secretion granules, but its precise biological functions
are not fully elucidated. CgA is processed in a tissue
specific manner into biologically active peptides with
various functions. One of these peptides is pancreast-
atin, which has a regulatory effect on secretion from
both endocrine and non-endocrine cells (Reinecke et al.,
* Corresponding author. Tel.: /47-73-590-389; fax: /47-73-598-
613
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1991; Nobels et al. 1998). CgA itself appears to
modulate the proteolytic processing of peptide hor-
mones and neuropeptides, and to be involved in both
the packing of peptides and in directing them to the
regulated pathway of secretion. In a clinical setting,
CgA seems to be one of the most important markers of
NE tumors (Syversen et al., 1993; Nobels et al., 1998;
O¨berg, 2000). CgA is used both as a serum and tissue
marker, and a future application may be its use in
visualization of NE tumors in patients.
Somatostatin (SST) is a widely distributed peptide
hormone which plays a pivotal regulatory role in
multiple target organs (c.f. Patel, 1999). It inhibits
secretion from a wide variety of both endocrine and
exocrine cells, it functions as a neurotransmitter in the
central nervous system (CNS), and it plays an important
role in regulation of cell proliferation and differentia-
tion. An antiproliferative effect of SST has been
demonstrated both in normal cells, in malignant cell
lines, and in tumors (Hofland and Lamberts, 1997;
Patel, 1999). SST exerts its effects through binding to
specific surface membrane receptors. Five different SST
receptor (SSTR) subtypes have been characterized
(SSTR1-5) (Schonbrunn et al., 1995; Hofland and
Lamberts, 1997; Patel, 1999).
The majority of NE tumors express a high density of
SSTRs and different SST analogs (e.g. octreotide) are
widely used both in diagnosis and therapy of these
tumors (Hofland and Lamberts, 1997; Wulbrand et al.,
1998; Pollak and Schally, 1998; O¨berg, 2000). Usually
more than one subtype is expressed, and the general
pattern of expression suggests a high frequency of
SSTR2 mRNA. Interestingly, a specific loss of SSTR2
subtype gene expression has been observed in human
pancreatic and advanced colorectal adenocarcinomas,
and this has been suggested to represent a growth
advantage in these tumors (Buscail et al., 1996). In
fact, it has recently been shown that SSTR2 gene
transfer mediates antitumor effect both in animals and
in-vitro (Rochaix et al., 1999). Thus, SSTR2 gene
transfer may represent a new therapy for cancer.
In spite of the extensive clinical use of SST analogs in
the management of NE tumors, the exact functional
significance of the presence of SSTRs, and how these are
being regulated, have still not been fully established
(Patel, 1999). The same is true concerning knowledge
about the function and regulation of the NE cell marker
CgA (Nobels et al., 1998). To this end, well-character-
ized in-vivo and in-vitro models are needed. The aim of
this study was to investigate whether the AR42J cell line
expresses CgA, and to characterize this cell line with
respect to the expression of the five known SSTRs. Our
findings lead us to propose that the AR42J cell line
might be a valuable experimental model to study
molecular mechanisms involved in the biology of NE
tumor cells.
2. Materials and methods
2.1. Cells and reagents
AR42J (rat pancreatic acinar cell derived, ATCC,
Rockville, MD, USA), Rat-2 (rat fibroblast, ATCC),
NRK-52E (rat epithelial, ATCC) and PC-12 (rat
pheochromocytoma, ATCC) cells were maintained in
Dulbecco’s Modified Eagle’s Medium (DMEM) with
4.5 g/l glucose (Gibco BRL, Life Technologies, Paisley,
Scotland), 1 mM Na-pyruvate (Gibco), 0.1 mg/ml L-
glutamine (Gibco), 10 U/ml penicillin/streptomycin
(Gibco), 1 mg/ml fungizone (Gibco) supplemented with
15% (AR42J), 10% (PC-12) or 5% (Rat-2, NRK-52E)
fetal calf serum (FCS) (Biological Industries, Beit
Haemek, Israel). RIN-5F (rat insulinoma, ATCC) and
RIN-14B (rat somatostatinoma, ATCC) cells were
grown in RPMI 1640 (Gibco) with 2 g/l glucose, 0.1
mg/ml L-glutamine, 0.04 mg/ml garamycin (Schering-
Plough Labo, Heist-op-den-Berg, Belgium), supplemen-
ted with 10% FCS.
Recombinant epidermal growth factor (EGF) (stored
lyophilized) was purchased from Biomedical Technolo-
gies (Stoughton, MA, USA). Gastrin-17 (stored lyophi-
lized) was obtained from Sigma (St. Louis, MO, USA).
Phorbol 12-myristate 13-acetate (PMA) (Sigma) was
dissolved in DMSO (1 mg/ml) and stored at /208.
Octreotide (Sandostatin) was purchased from Novartis
(Oslo, Norway).
2.2. Northern blot analysis
Total RNA from AR42J, PC-12, RIN-5F, RIN-14B,
Rat-2 and NRK-52E cells was isolated by phenol
extraction as previously described (Liabakk et al.,
1993). Twenty mg of each total RNA was electrophor-
esed on a formaldehyde agarose gel and blotted onto
nylon membranes (Roche Molecular Biochemicals,
Mannheim, Germany). Plasmids containing cDNA
fragments of CgA (Angelsen et al., 1997) or 18S (Bakke
et al., 2000) were linearized, and antisense RNA probes
labeled with 32P were generated by in-vitro transcription
according to standard protocols using SP6 or T7 RNA
polymerases. Probes were purified on NucTrap columns
(Amersham Pharmacia Biotech, Little Chalfont, UK).
Membranes were prehybridized for 4 h at 65 8C in 5/
sodium chloride/sodium-phosphate/EDTA buffer
(SSPE; 0.75 M NaCl, 0.05 M sodium phosphate, and
5 mM EDTA, pH 7.4), containing 50% formamide, 5/
Denhardt’s solution (0.1% bovine serum albumine
(BSA), 0.1% polyvinylpyrrolidine, and 0.1% Ficoll 400;
w/v), 0.5% sodium dodecyl sulfate (SDS) and 200 mg/ml
sonicated salmon sperm DNA (Sigma), then hybridized
in the same solution containing RNA probe (2/106
counts per min per ml) for a further 18 h at 65 8C.
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After hybridization, membranes were washed twice at
room temperature (RT) for 20 min with 2/ SSPE
containing 0.1% SDS and once at 65 8C for 20 min with
0.1/ SSPE containing 0.1% SDS. Washed membranes
were exposed to a storage phosphor screen for 15 min
(18S) or 18 h (CgA), and the screen was scanned on a
Phosphorimager 425 (Molecular Dynamics, Sevenoaks,
UK). Membranes were hybridized, first with the CgA
riboprobe, then by 18S. Probes were removed between
hybridizations by boiling in 0.1% SDS.
2.3. RT-PCR
AR42J was seeded out in growth medium at 0.9/106
cells per well in six-well plates and cultivated for 3 days
(subconfluent). Then, the cells were washed twice with
phosphate-buffered saline (PBS), and 500 ml lysis/bind-
ing buffer (100 mM Tris, pH 8.0, 500 mM LiCl, 10 mM
EDTA, pH 8.0, 1% LiDS, 5 mM dithiothreitol) was
added. DNA was sheared by forcing the lysate five times
through a 21 gauge needle by a 1/2 ml syringe. PolyA/
RNA was isolated from lysate (2.5/105 cells) with 125
ml oligo dT Dynabeads (Dynal, Oslo, Norway) accord-
ing to the protocol of the manufacturer, and eluted from
the beads in 20 ml Tris/HCl (10 mM, pH 7.5). Total
RNA from rat cerebral cortex was isolated and prepared
as previously described (Sandvik et al., 1995).
RT-PCR CgA was performed with 0.5 ml eluate with
1.25 U rTth DNA polymerase (Roche) according to the
procedure recommended by the manufacturer. cDNA
synthesis was performed at 61 8C for 40 min, followed
by PCR with 300 mM dNTP (Roche), 500 nM primers
and 3.0 mM Mn (OAc)2. PCR amplification was run for
28 cycles at 94 8C for 15 s, 55 8C for 15 s, and at 72 8C
for 30 s, followed by a final extension step for 3 min at
72 8C. The following PCR primers were used (S; sense,
AS; antisense): CgA-S: 5?-TCC ATG AAG CTC TCC
TTC-3? and CgA-AS: 5?-AGA AAG CTG CCT GTG
TTC-3?. The number of PCR-cycles was selected on the
basis of experiments with 28, 30, 32, 34 and 36 cycles,
which showed that 28 cycles yield quantitative results
within the linear range.
RT-PCR for SSTRs were performed by a two step
procedure. For reverse transcription, 5 ml of polyA/
RNA eluate or total RNA in a final volume of 30 ml,
containing 150 U MuLV reverse transcriptase (Roche),
3 ml of 10/PCR buffer (500 mM KCl, 100 mM Tris/
HCl, pH 8.3), 60 U RNAsin (Promega), 250 mM dNTPs
(Boehringer Mannheim), 5 mM oligo-d(T) (Amersham
Pharmacia Biotech) and 5 mM MgCl2 (Roche), was
incubated at 42 8C for 60 min, and then the enzyme was
denatured at 95 8C for 2 min. To ensure that the
specific RT-PCR products were exclusively dependent
on mRNA transcripts present, controls were performed
without reverse transcriptase.
For PCR amplification, 1 ml of cDNA was incubated
in a final volume of 20 ml with 1 U of AmpliTaqGold
(Roche), 2 mM MgCl2, 500 nM of each sense- and
antisense primer, 300 mM dNTP, and 2 ml GeneAmp
10/PCR Buffer (100 mM Tris/HCl, pH 8.3, 500 mM
KCl, 15 mM MgCl2) (Roche). PCR amplifications were
run for 28 (SSTR1), 35 (SSTR2), 34 (SSTR3), 40
(SSTR4) and 42 (SSTR5) cycles, respectively, at 94 8C
for 15 s, 66 8C for 15 s, and at 72 8C for 30 s, followed
by a final extension step for 7 min at 72 8C. The
following primers were used: SSTR1-S: 5? ATG GTG
GCC CTC AAG GCC GG 3?, SSR1-AS: 5?GGC AGT
GGC GTA GTA GTC AA 3?, SSTR2-S: 5? TCA TCA
AGG TGA AGT CCT CTG G 3?, SSTR2-AS: 5? AGA
TAC TGG TTT GGA GGT CTC CA 3?, SSTR3-S: 5?
TGC CAG TGG GTA CAG GCA CC 3?, SSTR3-AS:
5? CTG GAG GGC CAG ACC CTG GC 3?, SSTR4-S:
5? TGC GGG CTG GCT GGC AAC AA 3?, SSTR4-
AS: 5?GTA GTC CAG GGG CTC TTC CT 3?, SSTR5-
S: 5? CCT TTC CTG GCC ACG CAG AAC GC 3?,
SSTR5-AS: 5? GGC CAG GTT GAC GAT GTT GAC
3?.
To check whether comparable amounts of polyA/
RNA from each sample were used, RT-PCR reactions
for the house-keeping gene GAPDH were performed
using the following primers: GAPDH-S: 5?-CCCAT-
CACCATCTTCCAG-3? and GAPDH-AS: 5?-
ACAGTCTTCTGAGTGGCA-3?. PCR was run for 28
cycles at 94 8C for 15 s, 50 8C for 15 s and at 72 8C for
30 s, followed by a final extension step for 3 min at
72 8C.
The identity of the SSTR PCR products was checked
by informative restriction analysis using one or two
different restriction enzymes (Table 1). In each case, 8 ml
of the PCR product was treated at 37 8C for 2 h with
the appropriate enzymes (9-16 U) and restriction
enzyme buffers in a total volume of 20 ml.
2.4. Reporter plasmid experiments
The plasmid pXp100Luc containing 100 bp of the
proximal CgA promoter (Wu et al., 1995) was a
generous gift from Dr D. O’Connor (University of
California, San Diego, CA, USA). Cells (2/104) per
well were seeded out in 96-well plates and transfected
after 24 h with 0.12 mg luciferase reporter plasmid DNA
per well, using 0.35 ml Fugene transfection reagent
(Roche). After culture for 2 days in the presence of
plasmid and transfection agent, cells were treated with
agonists for 24 h followed by PBS wash (twice) and lysis
in 15 ml Promega lysis buffer. Luciferase activity was
measured by Turner Luminometer model TD-20/20
(Turner Designs, Sunnyvale, CA, USA) using the
Luciferase reporter Assay System (Promega Corp.,
Madison, WI, USA) as recommended by the manufac-
turer.
E. Hofsli et al. / Molecular and Cellular Endocrinology 194 (2002) 165/173 167
2.5. Detection of pancreastatin
AR42J cells were grown in 75 cm2 culture flasks for 4
days to reach confluence. The cells were then cultivated
for 24 h in serum free media (3 ml), before medium was
collected, centrifuged, and kept frozen at /80 8C until
assay. Cell lysates were prepared by lysis in distilled
water after one wash in PBS. Determination of rat
pancreastatin was performed by using a commercial
RIA kit (Peninsula Laboratories, Inc., San Carlos, CA,
USA) as described by the manufacturer. Briefly, pri-
mary antibody (rabbit anti-peptide serum) was added to
standards and unknown samples, followed by incuba-
tion overnight (4 8C). On the next day, 125I-peptide was
added and incubated for 24 h (4 8C). Then, addition of
goat anti-rabbit IgG, incubation 90 min at RT and
admixture of RIA buffer followed. The samples were
centrifuged for 20 min, supernatant aspirated, and assay
tubes counted. The detection limit of the assay was 5 pg/
ml, and the intra- and inter-assay variations were 4.9
and 3.8%, respectively, (Syversen et al., 1993).
2.6. Light-microscopical, immunohistochemical, and
ultrastructural examinations
Trypsinized AR42J cells were centrifuged at 4.000/
g . For the light-microscopical (LM) and immunohisto-
chemical (IHC) investigations, the pellet was conven-
tionally fixed in 10% neutral formalin, dehydrated, and
embedded in paraffin. Sections, about 4-5 micron thick,
on poly-L-lysine-coated slides, were used for the IHC
examinations. They were performed both by means of
the conventional avidin-biotin peroxidase procedure,
using the Vectastain ABC kit (Vector Lab., Burlingame,
CA, USA), and by applying the Tyramid Signal
Amplification (TSA) technique, using the ‘TSA indirect
kit’ (NEN LifeSci. Products, Boston, MA, USA), as
recently described (Qvigstad et al., 1999). The CgA
antiserum was provided by Incstar (Stillwater, MN,
USA), known to be immunoreactive (IR) in rat NE cells.
It was applied at a dilution of 1/500. For the Syn IHC
examination, the monoclonal mouse anti-Syn anti-
serum, provided by Dako (Glostrup, Denmark) was
employed with the dilution 1/20. For the neuron-specific
enolase (NSE) IHC studies, the ‘anti rat NSE’ anti-
serum, provided by Polysciences (Warrington, PA,
USA) was used, dilution 1/500.
For the electron microscopical (EM) investigations,
the pellet was fixed in 2% neutral glutaraldehyde, post-
fixed in 2% osmium tetroxide, contrasted with 1% lead
citrate and 4% uranyl acetate, and conventionally
embedded in Epon. Semi-thin sections were cut and
stained with toluidine blue for orientation and trimming
of the blocks. Finally, from the areas selected, conven-
tional ultrathin sections were cut and analyzed by means
of our transmission EMs (JEOL 100CX and Phillips SEI
Tecnai 12).
2.7. Proliferation assay
Proliferation rate was determined by measuring DNA
synthesis using the Cell proliferation ELISA BrdU (5-
bromo-2?-deoxyuridine) kit (Roche). AR42J cells (2/
103) were seeded out in 96-well microtiter plates in 150
ml serum-containing medium. After 24 h the cells were
washed with 200 ml serum-free medium before treatment
with gastrin and/or octreotide in a final volume of 100
ml. After 24 h, BrdU-labeling solution (10 ml per well)
was added, and the cells were cultured for an additional
18 h before incorporation of BrdU was measured as
described by the manufacturer. Briefly, after removing
the labeling medium, the cells were fixed and DNA
denatured in one step by adding 200 ml FixDenat-
solution per well for 30 min at RT After removing
FixDenat-solution, 100 ml anti-BrdU-POD working
solution was added to each well, and incubated at RT
for 90 min. The cells were then rinsed three times with
200 ml washing solution before 100 ml substrate solution
was added to each well. After 3 min the light emission of
the samples (RLU/relative luminiscence units) was
measured in a microplate luminometer (Fluoroskan
Ascent FL, Labsystems, Helsinki, Finland).
Table 1
Restriction enzymes used, and expected post-cleavage product length (bp), for verification of amplified SSTR (SSTR1-5) products
PCR-product Expected length (bp) Restriction enzymes Expected post-cleavage length (bp)
SSTR1 318 BsaH1 149169
PvuII 26949
SSTR2 414 BamH1 22392
PvuII 220194
SSTR3 328 BamH1 26959
PvuII 209119
SSTR4 311 PvuII 184127
SSTR5 549 BsaH1 174375
Sph1 426123
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2.8. Statistics
Statistical analysis were performed using the Student’s
t -test.
3. Results
3.1. AR42J cells express CgA mRNA
To determine whether AR42J cells express the NE cell
marker CgA, we used Northern blot analysis. As shown
in Fig. 1, a distinct hybridization band of a size
corresponding to the reported length of rat CgA
mRNA (2.1 kb) was detected in AR42J. This was
confirmed by RT-PCR (data not shown). The rat NE
cell lines PC-12 (pheochromocytoma) and RIN-5F
(insulinoma) were used as positive controls, as these
cell lines have been shown to express CgA mRNA
(Rausch et al., 1988; Swarovsky et al., 1994). The level
of CgA in AR42J was comparable to the level in PC-12.
We found CgA gene expression also in the somatosta-
tinoma cell line RIN-14B (Fig. 1). This has not been
reported earlier. The rat fibroblast Rat-2 and the rat
epithelial NRK-52E cell lines were used as negative
controls (Fig. 1).
3.2. Gastrin and EGF upregulate CgA gene expression
In order to study the regulation of CgA gene
expression in AR42J, we performed CgA promoter
reporter plasmid experiments. Gastrin, EGF and PMA
induced a moderate (136, 77 and 114%, respectively)
transcriptional upregulation of CgA after 24 h (PB/
0.001) (Fig. 2). Gastrin and EGF are both known to
activate protein kinase C (PKC) in AR42J cells (Stepan
et al., 1999). Since PMA is known to exert its effect via
both classical and novel diacylglycerol (DAG)-respon-
sive PKCs (Newton and Johnson, 1998), the PMA-
induced increase (114%) in CgA promotor activation
suggests that PKC is involved in mediating CgA
promoter transactivation in AR42J cells.
3.3. AR42J cells secrete pancreastatin
In order to confirm translation of CgA mRNA into
protein, we looked for the cleavage product pancreast-
atin in the cell medium. After incubation of confluent
AR42J cells (grown in 75 cm2 culture flasks in a volume
of 3 ml) in serum free media for 24 h, the concentrations
of pancreastatin were found to be in the range of 69-162
pg/ml, with a mean level of 96.59/30.5 pg/ml (n/6).
These ranges lie within the steep part of the standard
curve. We also detected pancreastatin in AR42J cell
lysates (data not shown).
3.4. Some AR42J cells are equipped with NE secretion
granules and are faintly IR to NE markers
In order to examine whether our AR42J cells fulfil the
classical histopathological criteria of being a NE par-
enchymal cell, we examined the LM, IHC, and EM
features of the cells. We focused our attention on four
major NE criteria, namely the LM/IHC detection of
CgA, Syn and NSE IR, as well as the actual EM
demonstration of typical NE secretion granules in the
cytoplasm of clear cells of NE appearance.
Only a faint IR could be discerned in a small minority
of the AR42J cells when antisera against CgA were used.
After the application of the TSA technique, a more
convincing IR was seen. However, the CgA/TSA IR was
still confined only to a small minority of the cells. This
was also the case when antisera against Syn and NSE
Fig. 1. Northern blot analysis of CgA. 20 mg of total RNA from
AR42J, and from the NE cell lines RIN-5F (insulinoma), PC-12
(pheochromocytoma) and RIN-14B (somatostatinoma) were electro-
phoresed in 1% agarose-formaldehyde gels, electroblotted onto nylon
membranes, and hybridized with RNA probes for CgA and 18S. The
indicated size (kb) of CgA was obtained by comparison with the sizes
of 18S and 28S rRNA. As negative controls were used the Rat-2
(fibroblast) and NRK-52E (epithelial) cell lines. The results shown are
representative for three independent experiments.
Fig. 2. Activation of the CgA reporter plasmid pXp100 AR42J cells
were transfected with CgA promoter reporter plasmid pXp100 (Wu et
al., 1995) and treated with either 50 ng/ml EGF, 50 nM gastrin (G-17)
or 100 ng/ml PMA for 24 h with quadriplicate parallels per condition.
Results are shown as mean value9/S.E.M. of one representative
experiment, and are expressed as fold induction compared with
untreated cells (* indicates significant difference with untreated cells;
PB/0.001). Similar results were obtained in two other experiments.
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were used. The Syn IR was more distinct than those of
CgA and NSE.
EM revealed that only a minority population of
AR42J displayed a fine structure, compatible with the
idea that they might be of NE nature (Fig. 3). Like the
clear cells of the ‘Helle-Zellen-System’ originally dis-
covered by Friedrich Feyrter in the 1930’s in the gastro-
entero-pancreatic (GEP) organs (Falkmer, 1993; Falk-
mer and Wilander, 1995), their cytoplasm was found to
be less electron dense than that of their non-NE
counterparts. They were observed to be well equipped
with cytoplasmic organelles, mainly mitochondria, lyso-
somal bodies, and an endoplasmic reticulum (ER) of
both rough and smooth type. In addition, a few typical
NE secretion granules appeared (Fig. 3; inset). They
were displaying a fine structure that was rather com-
monplace, an electron dense, homogeneous core of non-
crystalline shape, surrounded by a moderately broad
halo and a thin granule membrane. Practically no cells
were found containing numerous NE secretion granules.
The overall structure of the AR42J cells was that of cells
from a poorly differentiatied neoplastic parenchyma
with numerous mitotic figures. The absence of any
densely granulated NE cells indicated that the cells
with NE features were rather immature.
3.5. AR42J cells express SSTR subtype 1, 2, 3 and 5
There are conflicting results as to the question of
which SSTR subtypes AR42J cells express (Vidal et al.,
1994; Froidevaux et al., 1999). By RT-PCR analysis, we
could show the presence of mRNA of the four SSTR
subtypes 1, 2, 3 and 5 in AR42J cells (Fig. 4). This is the
first report of SSTR5 expression in AR42J. SSTR4
mRNA was not detected. Each analysis was repeated at
least five times. Contamination with genomic DNA was
ruled out by performing PCR on samples where reverse
transcriptase had been omitted in the cDNA synthesis
step. The PCR reaction for each of the five SSTR
subtypes was verified by using rat cerebral cortex as
positive control, as this tissue has been shown to express
transcripts of all the five SSTRs (Bruno et al., 1993;
Thoss et al., 1995). The specificity of each PCR product
was verified by informative restriction analysis. Fig. 5
shows that all specific SSTR PCR products exhibited
the expected restriction fragment sizes (see Table 1).
3.6. Proliferation studies
Expression of SSTR mRNA in cancer cell lines is not
always coupled with the expression of functional cell
surface receptors, as assessed by classic competitive
binding or proliferation studies (Fisher et al., 1998). In
order to confirm the existence of functional SSTRs in
AR42J cells, we examined the effect of the SST analog
octreotide on gastrin-induced proliferation (Scemama et
al., 1987; Seva et al., 1990; Watson et al., 1992).
Octreotide binds with a high affinity to SSTR2, with a
moderate affinity to SSTR3 and 5, and with a very low
affinity to SSTR1 and 4. Octreotide, at a concentration
of 0.1 nM, strongly inhibited gastrin-induced prolifera-
tion (Fig. 6). The effect was highly significant (P/
0.0011) at 0.4 nM gastrin. Our finding confirms the
expression of functional SSTRs in AR42J.
Fig. 3. Fine structure of an AR42J cell and one of its secretion
granules (inset). Low-power EM, showing the ultrastructural features
of an AR42J cell equipped with secretion granules of NE type (‘SG’;
inset; upper left corner). The cytoplasm of the cells of this minority
population cell type was found to be of lower electron density than
that of the adjacent AR42J cells in the pellet (upper right corner),
forming the majority cell population of the pellet. In addition to
mitochondria, a well developed endoplasmic reticulum (‘ER’; inset,
upper left corner), both of smooth and rough type, and several kinds of
lysosomal bodies occurred. The secretion granules of NE type formed
only a small minority of the cytoplasmic organelles. The bars give the
actual lengths of 5 mm (main electron micrograph) and 0.5 mm (inset),
respectively. Thus, the diameter of the secretion granule in the inset
amounts to approximately 136 nm.
Fig. 4. RT-PCR analysis of the five SSTR subtypes (SSTR1-5) in
AR42J cells. RT-PCR of polyA/RNA from AR42J was performed
with (/) or without (/) reverse transcriptase (RT), to rule out
contamination with genomic DNA. RT-PCR of total RNA from rat
cerebral cortex (c) was used as positive control. PCR products were
visualized in ethidium bromide stained 1.2% agarose gels. The marker
(M) is a 100 bp DNA ladder molecular weight standard (Gibco), and
the estimated PCR products are the following: SSTR1: 318 bp, SSTR2:
414 bp, SSTR3: 328 bp, SSTR4: 311 bp, SSTR5: 549 bp. To ensure
that comparable amounts of RNA were used in RT and RT PCR,
GAPDH RT-PCR was performed. The results shown are representa-
tive of at least five experiments.
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4. Discussion
Here we demonstrate, for the first time, that pancrea-
tic acinar AR42J cells express the rather specific NE
marker CgA, and that this expression is transcription-
ally regulated by the growth factors gastrin and EGF.
The sparse occurrence of typical NE secretion granules,
supposed to contain CgA, combined with the faint CgA,
Syn, and NSE IR, indicate that the cells are of a rather
poorly differentiated type. Furthermore, we show that
AR42J cells express mRNA of all SSTR subtypes,
except SSTR4. Our findings indicate that the AR42J
cell line could serve as a valuable experimental model to
study the regulation of CgA and SSTRs in poorly
differentiated NE tumor cells.
The fact that Rosewicz et al. (1992) were unable to
detect CgA in AR42J cells by immunoblotting may be
due to the low sensitivity of the immunoblotting
method. Our analyses show that the CgA mRNA levels
in AR42J cells are comparable to the levels in the NE
pheochromocytoma cell line PC-12 (Fig. 1). We also
detected CgA mRNA in the rat somatostatinoma cell
line RIN-14B. To the best of our knowledge, this is the
first report of CgA expression in RIN-14B. However,
the finding was not surprising, since others (Funakoshi
et al., 1990) have reported that CgA is expressed in the
human somatostatinoma cell line QGP-1.
We found a moderate transcriptional activation of
CgA in AR42J upon treatment with gastrin and EGF
(Fig. 2). Gastrin-induced regulation of CgA promotor
activity has previously been shown in gastric carcinoma
cells (Ho¨cker et al., 1998). However, Weiss et al. (2001)
could not detect any upregulation of neither CgA
mRNA (Northern blot), nor CgA protein (RIA), upon
treatment with EGF in neuroblastoma cell lines. This
may be due to a lower sensitivity of the Northern blot
method as compared with reporter plasmid analysis
used in the present study. However, it may also indicate
that CgA expression is not inducible by EGF in all NE
cell types. In conclusion, the demonstration that CgA
gene expression is regulated by gastrin and EGF, and
that CgA mRNA is translated into protein in AR42J,
strongly suggest a physiologically important role of CgA
in this pancreatic cell line.
Even though AR42J cells are known to express both
functional SSTRs (Viguerie et al., 1988) and their
mRNAs (Taylor et al., 1994; Vidal et al., 1994;
Froidevaux et al., 1999), there are conflicting results as
to which subtypes these cells express. Vidal et al. (1994)
found high levels of SSTR2 PCR products, and only low
levels of SSTR1 and 3. Froidevaux et al. (1999), on the
other hand, were unable to detect SSTR3 or SSTR5
mRNA, and concluded that AR42J cells can be
considered to be cells expressing exclusively SSTR2.
Their study was, however, limited to examining the
expression of just the three octreotide-binding receptor
subtypes, SSTR2, SSTR3, and SSTR5. Our finding that
the AR42J cells express four of the five SSTRs has, as
far as we know, not been reported previously. At least
any SSTR5 expression has not previously been detected
in AR42J cells. We were unable to detect SSTR4
mRNA, which has not been reported investigated by
others.
Wulbrand et al. (1998) found a widely varying
expression pattern of the five SSTR subtypes in different
types of NE gastro-entero-pancreatic (GEP) tumors.
However, almost 20% of the GEP tumors were found to
express four or five SSTR subtypes. Thus, it is obviously
of great importance in investigations of the exact
functional significance of SSTR expression to have
access to experimental models in which the NE tumor
cells express several SSTR subtypes. The AR42J cell line
fulfils these criteria, and thus has an advantage over
SSTR transfected cell lines which in most cases express
only one receptor subtype.
Fig. 5. Informative restriction enzyme analysis of amplified SSTR
(SSTR1-5) products. Reactions were performed as described in Section
2. M: 100 bp ladder. Shown are uncleaved PCR product of each
receptor, and the restriction enzyme pattern obtained with the different
enzymes used. See Table 1 for expected post-cleavage product length
(bp).
Fig. 6. Effect of octreotide on gastrin-induced proliferation in AR42J
cells. Proliferation was measured by using the BrdU proliferation kit,
as described in Materials and methods. AR42J cells were stimulated
with gastrin (0.4 and 10 nM G-17) in the absence (m-m) or presence of
octreotide (0.1 nM) (k-k) with quadriplicate parallels per condition.
Results are shown as the mean value9/S.E.M. of one representative
experiment, and are expressed as relative light units (RLU). Similar
results were obtained in two other experiments. *P/0.0011.
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SSTR scintigraphy is a well-established diagnostic
tool for staging of NE tumors, and may indicate
sensitivity to treatment with SST analogs (Chiti et al.,
2000). More recently, radiotherapy of SSTR positive
tumors with radiolabeled SST analogs has been carried
out with survival benefit (McCarthy et al., 2000). In
addition, because of their nearly universal inhibitory
actions on the release of peptide hormones and growth
factors, SST analogs are regarded as the main choice for
symptomatic treatment of hormone-related syndromes
often related to NE tumors (Hofland and Lamberts,
1997; O¨berg, 2000). In light of this extensive clinical use
of SST analogs, it will be of great interest to elucidate
molecular mechanisms involved in regulation of the
expression of the different SSTR subtypes, since this
may provide strategies to upregulate SSTRs in vivo. Our
results lead us to suggest that the AR42J cell line could
be a valuable experimental model for this purpose.
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Abstract
The aim of the present work is to identify molecular markers that allow classification of gastric carcinoma with respect to
important clinicopathological parameters. Gastric adenocarcinomas were subjected to cDNA microarray analysis with a 2.504
gene probe set. Using the Rosetta rough-set based learning system, good classifiers were generated for gene-expression based
prediction of intestinal or diffuse growth pattern according to Laure´n’s classification and presence of lymph node metastases.
To our knowledge, this is the first study on gastric carcinoma in which molecular classification has been achieved for more than
one clinicopathological parameter based on microarray gene expression profiles.
q 2004 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
Although the incidence of gastric adenocarcinoma
is declining, this neoplastic disease is still the second
most frequent cause of cancer death world-wide.
Gastric carcinomas are often not detected until at an
advanced stage; consequently, the 5-year survival
rates are low and most often in the order of 10–20%.
Variables such as size, microscopic differentiation
and growth pattern, depth of infiltration as well
as metastases in regional lymph nodes or in remote
organs and tissues, all play important roles in
treatment and prognosis. Carcinomas of the stomach
have been the subject of numerous kinds of clinico-
pathological classifications, often based on gross
features and/or microscopic growth pattern and
differentiation. In Scandinavian countries, the preva-
lent classification is that of Laure´n from 1965,
subdividing the gastric adenocarcinomas into two
major types, the intestinal and the diffuse [1].
Knowledge about the molecular features of gastric
carcinoma has increased rapidly. Genetic changes
include amplification of the c-erbB2 gene, mutations
of ras, APC and p53 genes [2] and truncation of
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E-cadherin [3]. Loss of heterozygosity in advanced
gastric carcinomas frequently implicates loci on
chromosomes 1, 5, 7, 12, 13 and 17 [2]. The tumor
cells also often show overexpression of the Ras
oncogenes and cyclins [4,5]. Multiple autocrine loops
may be involved, cytokines may be overexpressed,
and gastric carcinomas may express regulatory
peptides, like epidermal growth factor (EGF) [6,7],
transforming growth factor alpha (TGF-a) [6,7],
platelet-derived growth factor (PDGF) [6] and
insulin-like growth factor II (ILGF-II) [6]. Hepatocyte
growth factor (HGF) and its receptor c-met are
frequently overexpressed [8,9]. The classification
according to Laure´n also corresponds to some degree
with genetic abnormalities [6,10,11]. The objective of
the work presented here was to examine the gene
expression patterns of primary tumors in patients with
gastric carcinoma by DNA microarray in order to
search for correlations between gene expression and
selected clinical and tumor parameters. We sought
patterns that characterize both aspects of biological
interest, like levels of serum gastrin and localization
of tumor in the stomach, and gene expression-based
classifiers for parameters important for treatment and
prognosis. To this end we analysed gene expression
data with a machine learning formalism based on
rough sets [12], and the Rosetta toolkit [13]. The
quality of the classification was assessed with a cross-
validation scheme and tested on random data.
2. Materials and methods
2.1. Patients
The study was approved by the local Institutional
Review Board, and the patients gave written informed
consent. Tumor samples were taken from patients with
gastric carcinoma who underwent gastric resection.
The tumors were selected according to Laure´n’s
classification, including approximately equal numbers
of tumors with intestinal and diffuse growth pattern and
avoiding tumors with an indeterminate histopatholo-
gical pattern. Preoperative blood samples were taken
for gastrin measurement. The extent of the disease was
assessed preoperatively by chest X-ray, abdominal
ultrasound and CT scan, and the abdominal cavity was
explored during the surgery. The resectates were
inspected and the tumors described by localization
(cardiac, corpus, antral), penetration of the gastric wall
and lymph node metastases. Histopathological assess-
ment included tumor classification according to
Laure´n, depth of invasion and examination of lymph
nodes in the resectate. Radioimmunoassay for gastrin
was done as previously described [14].
2.2. Tumor material
Tumor samples were collected in the operating
room as soon as possible after resection. Tumor tissue
was identified macroscopically, dissected from the
resectate and preserved on formaline, or snap frozen
and stored on liquid nitrogen. The formaline-fixed
material was processed using routine histopathologi-
cal procedures and stained with hematoxylin–eosin
before examination by an experienced pathologist
(SF). Frozen tissue was homogenized in a guanidi-
nium-isothiocyanate buffer with a rotating-knife
homogenizer, total RNA was extracted by ultracen-
trifugation on a cesium chloride cushion, precipitated,
purified using TRIzol (phenol-guanidinium-thiocya-
nate) (GIBCO BRL Life Technologies, New York,
NY), and examined for degradation by agarose
electrophoresis with evaluation of the 18S and 28S
ribosomal RNA bands. There was no degradation in
any of the samples used for microarray analysis.
2.3. Microarray procedures
Arrays were prepared using cDNA probes repre-
senting 2.504 sequence verified human genes
(Research Genetics, Huntsville, AL) (supplementary
material at http://www.lcb.uu.se/~herman/gastric/
gastric.html), including 1.500 genes defined in the
NCI Oncochip selection (http://resresources.nci.nih.
gov/). Additional information of cDNA clone prep-
aration is described in Ref. [15]. The probes were
printed in duplicate onto amino-silane coated glass
slides (Corning CMT-GAPS; Corning, Corning, NY)
using a printing robot constructed in collaboration
with NEMKO (Trondheim, Norway) after a prototype
developed at the National Human Genome Research
Institute (NHGRI), Bethesda, MD (http://www.nhgri.
gov/DIR/LCG/15K(HTML/).
Universal Human Reference RNA from Stratagene
(La Jolla, CA) consisting of total RNA from 10 different
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cell lines selected to optimize gene coverage on human
microarrays, and tumor sample total RNA (1 mg each),
were reverse transcribed and labeled with Cy3- and
Cy5-attached dendrimer, respectively, using the Geni-
sphere 3DNA dendrimer kit (Genisphere, Montvale,
NJ) as described in the manufacturer’s protocol and
previously by us [15]. Arrays were scanned separately at
532 and 633 nm using a confocal laser scanner
constructed in collaboration with NEMKO (Trondheim,
Norway) according to a prototype developed at NHGRI
(http://www.nhgri.nih.gov/DIR/LCG/15K/HTML/).
2.4. Data analysis
The microarrays were analyzed using Scanalytics’
MicroArray Suite with default settings. Several
normalization techniques, including global and print-
tip normalization [16], were tested on each array. We
found that global normalization most often gave the
highest correlation between the duplicate spots. Hence,
each array was globally normalized and further
analysis done on log2 transformed, background
corrected ratios. Unreliable spots were removed from
the arrays after scatter plot analysis.
The microarrays were analyzed with regard to the
following parameters: histopathological classification
(Laure´n, diffuse or intestinal), site of primary tumor
(cardia, corpus or antrum), penetration of the stomach
wall or not, lymph node metastasis or not, remote
metastasis or not, and high or normal serum gastrin.
For each parameter, the tumor data contained two or
three classes, a ‘class’ is a value of a parameter that
may be assigned to a tumor sample (example: yes or
no for remote metastasis). Genes that were differen-
tially expressed between the classes of each par-
ameter, were identified using a bootstrap t-test [17].
The measurements from each gene probe were tested
separately by collecting the corresponding log2-ratios
from the microarrays, and the log2-ratios from the
probe duplicates were averaged. A gene was not
tested, if the ratios for both duplicate spots were
missing on more than 50% of the microarrays.
2.5. Generation of gene expression based classifiers
In order to generate classifiers for the six
parameters we used Rosetta [13], a rough set theory
[12] based supervised learning system. A classifier is
trained on a set of tumors with known classes (e.g. the
presence or absence of lymph node metastasis). The
trained classifier may then assign a class to a new
tumor (e.g. indicate from the gene expression pattern
of the new tumor if there is lymph node metastasis or
not). A training set was built using the log2-ratios of
the differentially expressed genes with the highest t-
statistic from the bootstrap analysis. Genes significant
at the P # 0:01 level were primarily chosen, and if
these were very few, genes at the P # 0:05 or P #
0:10 level were also used. Classifier performance was
optimized by adjusting the maximum number of
genes allowed in each classifier within a range of 10–
40 genes. The log2-ratios of each gene were then
discretized using frequency binning or Fayyad and
Irani’s discretization algorithm [18], converting
quantitative (numerical) data into qualitative (categ-
orical) data (eg. low, medium, high). Frequency
binning divides the range of the log2-ratios into k
intervals (or bins) so that the frequency of ratios is the
same in each interval. In our case, we used k from 2 to
4 intervals. Rosetta provides several learning algor-
ithms for producing rules. These algorithms and
discretization methods were tested for each clinical
parameter in order to determine the best classifier in
each case.
The classifiers were evaluated using leave-one-out
cross-validation, a method that has also been used by
others [19,20] for tumor classification. A new
classifier was learned for each sample by excluding
the sample from the training set and training the
classifier on the remaining samples. This classifier
was then used for classifying the left-out sample. This
process was repeated for all samples, and the quality
of the classifiers (sensitivity, specificity, area-under-
curve-(AUC)) was estimated on the basis of the
predictions made for each sample. Note that the gene
bootstrap selection step was included in the cross-
validation procedure so that for each iteration of this
procedure a new set of genes was selected and a
classifier was trained using these genes. This is
important since if the genes had been selected prior
to cross-validation procedure, the estimated perform-
ance could have been optimistically biased. Details of
the data analysis are given in the supplementary
material (http://www.lcb.uu.se/~herman/gastric/
gastric.html) and in Midelfart et al. [21].
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2.6. RT-PCR analysis
Confirmatory reverse-transcription polymerase
chain reaction (RT-PCR) analysis was done on four
different genes. The primer sequences used can be
found in supplementary material (http://www.lcb.uu.
se/~herman/gastric/gastric.html). RT-PCR analysis
was performed with 250 ng tumor total RNA and
1.25 U rTth DNA polymerase (Perkin Elmer, Boston,
MA), with cDNA synthesis at 61 8C for 40 min,
followed by PCR with 29 cycles at 94 8C for 15 s,
50 8C for 15 s, and at 72 8C for 30 s, and a final
extension step for 3 min at 72 8C. The number of
PCR-cycles was selected on the basis of preliminary
experiments which showed that 29 cycles yielded
quantitative results within the linear range. PCR
products were visualized by electrophoresis on a 2%
ethidium bromide agarose gel.
3. Results
3.1. Patient/tumor characteristics
Tumor samples were taken from 17 patients, 6
female (aged 45–80, median 70 years) and 11 male
(aged 49–93, median 73 years), all Caucasian. Nine
tumors were classified as intestinal and 8 as diffuse
according to Laure´n; 4 tumors were localized to the
cardiac, 7 to the corpus and 6 to the antrum region.
Thirteen patients had tumors penetrating the gastric
wall and 10 had lymph node metastases. Incomplete
clinical data made the presence of remote metastasis
evaluable for only 13 patients, of these 3 had
discernible remote metastases. Serum gastrin
measurements were available for 14 patients, of
these 5 had serum gastrin above the upper normal
value of 40 pM. In these patients median serum
gastrin was 104 (range 43–350) pM. Both sexes were
similarly distributed between the classes in each
parameter.
3.2. Microarray analysis-development and quality
assessment of the classifiers
The raw data from the microarray experiments can
be found as supplementary material (http://www.lcb.
uu.se/~herman/gastric/gastric.html). The genes ident-
ified by bootstrap analysis were used to develop
classifiers for the six selected parameters (Table 1).
Several classifiers had a very good accuracy and a
high AUC value, indicating that the classes of these
Table 1
Classifiers for clinical parameters
Parameter Predicteda Accuracy Sensitivity Specificity AUCb Total no. of
genes in CVc
Max. genes
in classifier
Prevalences
in the classes
Histopathological
classification (Laure´n)
16/17 0.94 1.00 0.88 0.93 17 10 9/8d
Lymph node metastasis 14/17 0.82 0.70 1.00 0.90 73 20 10/7e
Penetration of gastric wall 16/17 0.94 1.00 0.75 0.85 75 20 13/4e
Remote metastasis 13/13 1.00 1.00 1.00 1.00 161 40 3/10e
Localization of tumor 17/17 1.00 1.00 1.00 1.00 72 20 4/13f
Serum gastrin 11/14 0.79 0.89 0.60 0.66 14 10 5/9g
Classifiers obtained by ‘Rosetta’. The quality (accuracy, sensitivity, specificity, area-under-curve-AUC) of the classifiers is shown. Each
algorithm was evaluated with cross-validation, and it is the performance of the best algorithm which is presented. The number of genes that
occurs in at least one of the classifiers generated during cross validation is given. No rules or classifiers were combined, but the number of times
each gene was used during cross-validation was examined. This is reported in Table 3.
a No. predicted vs no. samples.
b Area-under-curve.
c Cross-validation.
d Intestinal/diffuse.
e Yes/no.
f Cardiac/noncardiac.
g High/normal.
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parameters could be predicted with a high level of
confidence using the microarray data. The best results
were usually obtained when not more than 10 or 20
genes with the highest bootstrap t-statistic were used
in a single classifier.
There is a considerable risk of overfitting the
classifier when there are only 3–5 samples in one
class, as is the case for penetration of the gastric wall,
remote metastasis, serum gastrin and localization.
Therefore, the significance of each classifier was
assessed with a permutation test, which estimated the
probability that the results had arisen by pure chance.
For each clinical parameter, we created 2000 random
data sets by shuffling the class labels of the parameter.
The full cross-validation procedure (including gene
selection with bootstrapping and learning with rough
set algorithms) was then repeated on each random
data set so that the AUC could be computed. A P-value
was estimated by counting the number of random data
sets that had an AUC greater than, or equal to, the
AUC obtained on the original data (Table 2). This
analysis showed that the classifiers for Lauren’s
histopathological classification, and lymph node
metastasis were convincingly significant. The classi-
fier for localization of tumor also showed a P-value
below 0.05 and should be considered significant.
Penetration of the gastric wall had a P-value slightly
greater than 0.05 and was a borderline case. This
classifier should thus be treated with more caution.
The classifiers for remote metastasis and serum
gastrin had P-values well above 0.1 and are probably
not usable.
3.3. The genes in the classifiers
From a molecular biological point of view, it is
highly interesting to examine the genes used by each
of the classifiers. The genes used in a given classifier
can distinguish between a tumor sample of one class
and a tumor sample of another class within a clinical
parameter (e.g. distinguish between presence and
absence of lymph node metastasis). Thus, these
genes are likely to encode proteins that play a role in
the underlying molecular biology of the parameter in
question. Table 3 shows a list of genes used by each
of the classifiers generated by cross-validation. It is
important to note that leave-one-out cross-validation
creates one classifier for each sample with this
parameter (that is 17 classifiers for all parameters
except for gastrin level and remote metastasis where
data were available for only 14 and 13 patients,
respectively). Thus, the number of classifiers in
which a given gene is used, indicates the general
importance of this gene in predicting the class of a
given patient sample for the parameter in question.
Genes that occur in a high proportion of the
classifiers for a given parameter are generally useful
for separating the classes within that parameter.
These genes are thus characteristic for that parameter
and may be of particular biological interest. For
example, ISG15 appeared in each of the 17 classifiers
that were created during cross-validation of the best
learning algorithm for lymph node metastasis. FAT,
on the other hand, occurred in only two of the
classifiers.
The classifier genes code for proteins with many
different functions; such as intracellular signal trans-
duction, protein synthesis, cell division and differen-
tiation, extracellular matrix components, cell adhesion
molecules and several more. We also find several
genes with unknown biological function. The classifier
genes are of clinical and biological interest, since their
expression is related to gastric carcinoma tumor
biology. In the following, classifier genes for the
different parameters are discussed in some detail.
3.4. Histopathology (Laure´n)-intestinal or diffuse
Only three genes were used in more than two
classifiers for these two histopathological classes.
One is BRCA2, which was expressed at a higher
Table 2
The probability of obtaining similar classification performance on
random data
Parameter P-value
Histopathological classification (Laure´n) 0.007
Lymph node metastasis 0.007
Localization of tumor 0.031
Penetration of gastric wall 0.059
Remote metastasis 0.195
Serum gastrin 0.391
The P-values are the estimated probability that the learning
algorithm (which was selected individually for each parameter) will
obtain an AUC value greater or equal to the AUC that it obtained on
the experimental data.
K.G. Nørsett et al. / Cancer Letters 210 (2004) 227–237 231
Table 3
Genes of classifiers for clinically relevant parameters
Symbol Name GeneBank AccNo No classifiers Highest level in
Intestinal (I) or diffuse (D)-Laure´n I D
BRCA2 Breast cancer 2, early onset H48122 17 £
SCAND1 SCAN domain-containing 1 W69127 17 £
RIN Ric (Drosophila)-like, expressed in neurons N53351 15 £
Lymph node metastasis (yes or no) Y N
LOC51058 Hypothetical protein AA053665 17 £
ISG15 Interferon-stimulated protein, 15 kDa AA406020 17 £
Homo sapiens cDNA FLJ14959 fis, clone PLACE4000156 AA159900 16 £
Homo sapiens, clone IMAGE:3948563 AA043772 16 £
DKFZP434J1813 DKFZp434J1813 protein AA504844 16 £
CACNB1 Calcium channel, voltage-dependent, beta 1 subunit W72250 15 £
Homo sapiens, clone MGC:2492, mRNA, complete cds AA620408 15 £
NAP4 Nck, Ash and phospholipase C binding protein AA625859 15 £
PPP1CC Protein phosphatase 1, catalytic subunit, gamma isoform AI015359 14 £
ESTs, Mod similar to JC5238 galactosylceramide-like prot AA071075 13 £
HAT1 Histone acetyltransferase 1 AA625662 13 £
MGC8471 Hypothetical protein MGC8471 AA447502 13 £
SEC4L GTP-binding prot homo to Sacc cerevisiae SEC4 T60109 12 £
DUSP3 dual specificity phosphatase 3 AA190339 11 £
NOLA2 Nucleolar protein family A, member 2 AA485675 11 £
RAB11A RAB11A, member RAS oncogene family AA025058 10 £
SNRPE Small nuclear ribonucleoprotein polypeptide E AA678021 10 £
TRIP10 Thyroid hormone receptor interactor 10 R49671 9 £
ESTs, Moderately similar to S47073 finger protein HZF2 AA281890 8 £
Homo sapiens, clone MGC:18257 AA495746 5 £
DARS Aspartyl-tRNA synthetase AA481562 5 £
CDH2 Cadherin 2, type 1, N-cadherin (neuronal) W49619 5 £
CA150 Transcription factor CA150 AA045180 4 £
PMAIP1 Phorbol-12-myristate-13-acetate-induced protein 1 AA458838 4 £
NDUFAB1 NADH dehydrogenase 1, alpha/beta subcomplex AA447569 4 £
CAMLG Calcium modulating ligand AA521411 2 £
PP Pyrophosphatase (inorganic) AA608572 2 £
IGSF3 Immunoglobulin superfamily, member 3 AI002566 2 £
MID1 Midline 1 (Opitz/BBB syndrome) AA598640 2 £
FAT FAT tumor suppressor (Drosophila) homolog AA159194 2 £
Cardiac (C) or non-cardiac (NC) location C NC
CDH2 Cadherin 2, type 1, N-cadherin (neuronal) W49619 17 £
PMAIP1 Phorbol-12-myristate-13-acetate-induced protein 1 AA458838 17 £
MRPL4 Mitochondrial ribosomal protein L4 AA490981 17 £
DUSP4 Dual specificity phosphatase 4 AA444049 17 £
CYP3A4 Cytochrome P450, subfamily IIIA, polypeptide 4 R91078 16 £
DUSP3 Dual specificity phosphatase 3 AA190339 15 £
SOS1 Son of sevenless (Drosophila) homolog 1 N51823 15 £
LOC51058 Hypothetical protein AA053665 14 £
RBSK Ribokinase T69020 14 £
ESTs, moderately similar to S47073 finger protein HZF2 AA281890 14 £
MTF1 Metal-regulatory transcription factor 1 AA448256 14 £
(Continued on next page)
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level in tumors with intestinal differentiation.
The product of this gene probably takes part in
DNA repair. Mutations in the BRCA2 gene have
been associated with increased susceptibility to
several malignant tumors, among these also gastric
carcinoma [22]. There is no previous information,
however, on any association of specific gastric
carcinoma subtypes with BRCA2 inactivation.
Table 3 (continued)
Symbol Name GeneBank AccNo No classifiers Highest level in
CDKN1B Cyclin-dependent kinase inhibitor 1B (p27, Kip1) AA630082 14 £
PMS1 Postmeiotic segregation increased 1 AA504838 13 £
NDUFS1 NADH dehydrogenase (ubiquinone) Fe-S protein 1 AA406535 12 £
UBE2E1 Ubiquitin-conjugating enzyme E2E 1 AA044025 12 £
KIAA1595 KIAA1595 protein AA496999 11 £
REG1A Regenerating islet-derived 1 alpha AA625655 9 £
CSE1L Chromosome segregation 1-like N69204 9 £
NOTCH3 Notch (Drosophila) homolog 3 AA284113 9 £
MGC8471 Hypothetical protein MGC8471 AA447502 7 £
ABR Active BCR-related gene W24076 6 £
RELA v-Rel avian reticuloendotheliosis viral oncogene homo A AA443546 5 £
LAMB1 Laminin, beta 1 AA019209 4 £
Similar to TEA domain family member 2 AA669124 4 £
PPAT Phosphoribosyl pyrophosphate amidotransferase AA873575 4 £
RAB18 RAB18, member RAS oncogene family AA156821 3 £
EIF2S2 Eukaryotic translation initiation factor 2, subunit 2 AA027240 3 £
Tumor penetrating gastric wall (yes or no) Y N
ADK Adenosine kinase R12473 16 £
RXRG Retinoid X receptor, gamma W96099 13 £
PRKCQ Protein kinase C, theta H60824 12 £
ITGA3‘ Integrin, alpha 3 AA424695 9 £
SCEL Sciellin AA455012 8 £
ESTs R44752 8 £
LGALS3 Lectin, galactoside-binding, soluble, 3 (galectin 3) AA630328 7 £
TRD@ T cell receptor delta locus AA670107 6 £
PEG3 Paternally expressed 3 AA459941 4 £
ZNF238 Zinc finger protein 238 R79722 3 £
RUNX3 Runt-related transcription factor 3 N67778 3 £
PPARD Peroxisome proliferative activated receptor, delta N33331 3 £
HNF3G2 Hepatocyte nuclear factor 3, gamma R99562 3 £
OMD osteomodulin N32201 3 £
RI58 Retinoic acid- and interferon-inducible protein (58 kD) W24246 3 £
ESTs, weakly similar to gonadotropin ind trans rep-1 R09497 2 £
TRIP7 Thyroid hormone receptor interactor 7 AA431611 2 £
DCTN1 Dynactin 1 (p150, Glued (Drosophila) homolog) AA488221 2 £
FLJ10808 Hypothetical protein FLJ10808 AA443582 2 £
EDG4 Endothelial diff, lysophos acid G-prot-coup rec, 4 AA419092 2 £
RAB1 RAB1, member RAS oncogene family N69689 2 £
ZNF228 Zinc finger protein 228 N62629 2 £
GRIA1 Glutamate receptor, ionotropic, AMPA 1 H23378 2 £
Genes that occur in two or more of the classifiers for one of these parameters: histopathological classification (Laure´n), lymph node
metastasis, localization of tumor and penetration of the gastric wall. The number of classifiers in which a given gene is used is given. For
example, ISG15 appeared in one rule in each of the 17 classifiers that were created during cross-validation of the algorithm that had the best
performance for lymph node metastasis and this frequency estimates the stability of a gene in the classifier. Total number of classifiers was 17
for each parameter. Two classes are given for each parameter. The class with the highest mean level of expression compared to a common
reference material is indicated for each gene. UniGene Build 136 was used.
K.G. Nørsett et al. / Cancer Letters 210 (2004) 227–237 233
3.5. Lymph node
Most of the lymph node metastasis classifier genes
that are included in more than two classifiers are
expressed at a higher level in tumors with lymph node
metastasis. The lymph node metastasis classifier gene
N-cadherin (CDH2) has previously been found in
gastric adenocarcinoma [23] and upregulation corre-
lates with invasiveness in carcinomas of the breast and
prostate [24,25]. The thyroid hormone receptor
interactor 10 (TRIP10) regulates microtubular struc-
ture and may induce cellular motility and spreading
by binding to CDC42 [26].
3.6. Localization—gastric cardia vs. other locations
Most of the genes used in these classifiers are
expressed at a higher level in tumors from the cardia.
Among these are N-cadherin (CDH2) which is
expressed in a subgroup of gastric carcinomas [23],
cyclin-dependent kinase inhibitor 1B (CDKN1B)
which has been found underexpressed in advanced
gastric carcinoma compared to early carcinoma [27],
and the cytochrome p450 subfamily IIIA polypeptide
4 (CYP3A4) which is overexpressed in intestinal
metaplasia and in some well differentiated gastric
carcinomas [28]. The nuclear factor-kB (RELA) has
been shown to be overexpressed in gastric adenocar-
cinoma of the proximal stomach [29]. Moreover, a
low expression level of the regenerating islet-derived
1-a peptide (REG1A) is used in two of the classifiers
that identify cardiac localization. This peptide is
mainly found in the oxyntic mucosal ECL cells which
are scarce in the cardia [30].
3.7. Penetration of the gastric wall
Several of the classifier genes that are expressed
at a higher level in tumors penetrating the gastric
wall, are associated with cellular adhesion and
migration. Galectin 3 (LGALS3) binds to laminin
and correlates to metastasis and local invasion in
colorectal cancer [31] and in carcinoma of the breast
[32], and integrin a3 (ITGA3) is essential for
cellular adhesion and migration. Also, tumors
penetrating the gastric wall exhibit higher
expression levels of the glutamate AMPA 1 receptor
(GRIA1), whose antagonists are reported to inhibit
proliferation, motility and invasive growth of color-
ectal carcinoma-derived cell lines [33].
3.8. Verification of results
The four genes DSC2, BM1, PPP1CC and IGF1,
were analysed by RT-PCR in five tumor samples each.
For 80% (8 of 10) of the gene-tumor sample-
measurements with a microarray ratio less than 0.6,
RT-PCR also indicated underexpression relative to
the reference RNA. None of the tested genes were
significantly overexpressed (microarray analysis) in
tumor samples compared to the reference RNA. Thus,
the results of the RT-PCR analysis were consistent
with the expression profiles obtained through cDNA
array hybridization.
4. Discussion
In the present study we have shown that microarray
analysis of gastric carcinoma, a complex solid tumor
with multiple cellular elements, can produce data that
are significantly related to important clinicopatholo-
gical features. Moreover, we were able to generate
reliable classifiers for several clinically important
parameters. Our work also identified several genes
that were not previously known to display character-
istic expression patterns in gastric carcinoma.
The rough set based system Rosetta was used to
build classifiers in this study. Other classification
methods such as nearest neighbour, discriminant
analysis, neural networks, support vectors machines,
decision trees could also have been used. Our choice
was made for two reasons. First, the rough set
approach creates decision rules, making interpretation
of the classifier easier. Second, we obtained good
classifiers with the rough set approach. In a recent
study, Dudiot et al. [34] compared several different
classification methods on three different data sets.
They found that diagonal linear discriminant analysis
and nearest-neighbour gave the best performance.
Therefore, we also trained classifiers using one of
these methods, namely diagonal linear discriminant
analysis, and compared its performance to that of the
rough set classifiers. The rough set classifiers out-
performed discrimant analysis and obtained the best
AUC for all of the clinical parameters (described in
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detail in Midelfart et al. [21]). Hence, the rough set
approach seemed to be well-suited for this analysis.
Some of the genes which we found to be
differentially expressed between gastric carcinoma
tumor samples have recently been found by others to
be highly expressed in gastric carcinomas [35,36],
supporting the validity of our data. This applies to
IMPDH2, ITGA3, TRIP10, CSPG2, CDH17 and
COL6A3. Moreover, IGFBP2, for which we found
low levels of expression in tumors penetrating the
gastric wall, has previously been reported to be
downregulated in gastric carcinoma [36]. The gene
expression measurements in the present study are
derived from co-hybridization of tumor RNA with a
common reference RNA sample. The results thus do
not indicate whether a gene is over- or underexpressed
in gastric carcinoma per se. However, expression
levels can be compared between individual tumor
samples, and related to parameters associated with
these samples. Since gastric carcinomas are tumors
with cellular heterogenity, it is not possible to know
whether a specific gene is expressed in the malignant
cells or in the stroma. However, the data reveal gene
expression features that are important in the inter-
action between tumor and stromal cells. Knowledge
on such interactions is necessary to understand tumor
biology, like the regulation of metalloproteinases or
their inhibitors in gastric carcinoma tumor cells and
stroma [37,38].
Some of the classifier genes code for proteins that
are important in the context of defined clinical
parameters, others have no known relation to
malignant disease. Moreover, many classifier genes
code for proteins with poorly characterized or
completely unknown biological functions. Thus, our
study identifies new genes that may be of potential
clinical and biological interest in gastric carcinoma.
Although the findings in a single study like this
must be handled with great care, our methods
constitute one possible approach towards developing
a clinically useful molecular classification of tumors.
From primary gastric tumors, we have developed
classifiers that characterize gastric carcinomas with
respect to clinico-pathologically important par-
ameters such as lymph node metastasis. Moreover,
with the molecular methods used here ordinary
endoscopic biopsies give ample total RNA for
analysis of factors that are important in the surgical
decision-making process and in the choice of adjuvant
cancer therapy. However, all the patients were of
Norwegian/Caucasian origin, and at the present stage
one should be careful concerning the general
applicability of the classifiers. The results will have
to be verified in a larger series of tumors, probably
also in different patient populations.
Interestingly, we were able to produce a classifier
that distinguishes the diffuse and intestinal forms of
gastric carcinoma as described by Laure´n [1]. Like
Boussioutas et al. [39], our results indicate that
Laure´n’s classification reflects significant molecular
differences in gastric carcinomas. However, Bous-
sioutas et al. made no attempt to use supervised
methods to predict the class of samples for these
parameters. Hippo et al. [35], could not find that their
two-way clustering gene expression analysis provided
classifiers for histopathological features in their
gastric carcinoma material. If the results of Boussiou-
tas et al. and ourselves can be confirmed, a gene
expression based classification of gastric carcinoma
will probably be more precise than the presently used
histopathological examination. Moreover, the classi-
fier genes may provide further insight in the molecular
processes that differentiate these two histopathologi-
cal forms of gastric carcinoma.
The classifier that distinguishes cardiac from non-
cardiac gastric carcinomas is of particular biological
interest, since cardiac adenocarcinoma shows a
clinicopathological and epidemiological pattern
different from the more distal gastric carcinomas
[40]. In contrast to adenocarcinomas of the corpus or
antrum, the incidence of cardiac adenocarcinomas
increases [41], and the cardiac tumors are unrelated to
infection with Helicobacter pylori. It is interesting to
note that when we first tried to predict all locations of
the tumors (cardiac, corpus, antral), we obtained poor
results and no good classifiers were found. We could,
however, train a classifier that separated cardiac
tumors from corpus and antral tumors combined.
This indicates that cardiac tumors have a gene
expression pattern that is clearly different from tumors
with corpus and antral localization. Some of the
localization classifier genes are clearly related to
gastric carcinoma, like N-cadherin, but the only gene
known to be region-specific is regenerating islet-
derived 1a peptide, which is only expressed in the
ECL cells of the oxyntic mucosa, and barely
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expressed in the cardiac region [42]. The localization
classifier genes are obvious targets for further studies.
A number of studies have shown that microarray
analysis may be used to establish gene expression
profiles identifying tumor subgroups that correlate
with clinicopathological parameters. This has been
done for breast cancer [43], lymphoma [44], and
esophageal carcinoma [45]. Moreover, microarray
gene expression data have been used to classify and
predict leukemia subtypes [19], breast cancer estrogen
receptor status [46–48] and the prognosis for patients
with renal clear-cell carcinoma [49]. In the present
study, we have demonstrated classification and
prediction of several different parameters based on
one set of microarray gene expression profiles. To our
knowledge, this is the most complex set of classifiers/
predictors reported for different clinically and bio-
logically relevant features of gastric adenocarcinoma.
This work should be considered a first attempt to
produce clinically and biologically useful molecular
classifications for this type of cancer.
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2Abstract
Long-term therapy with potent acid inhibitors is the most common treatment for 
gastro-esophageal reflux disease. Administration of proton pump inhibitors (PPI’s) 
causes profound and continuous hypochlorhydria by inhibition of the proton pump 
(H+/K+-ATPase) in gastric parietal cells. Long-term hypergastrinaemia increases 
mucosal thickness and ECL cell density in oxyntic mucosa, and results in 
development of gastric carcinoids in experimental animals. Knowledge of the effect 
on mucosal gene expression of PPI’s given to humans in ordinary, therapeutic doses is 
limited. Eight patients suffering from gastro-esophageal reflux disease were included 
in this study. Endoscopic biopsies were taken from the corpus mucosa before and 
towards the end of a three-month treatment with the PPI esomeprazole. Microarray 
analysis identified 149 differentially expressed genes. Of these 56 were induced, and 
93 were repressed. A high proportion of genes with changed gene expression levels in 
the presence of proton pump inhibitors are involved in proliferation, apoptosis and 
stress response. This work identified many genes that were not previously known to 
be affected by inhibition of gastric acid secretion. Further characterization of the 
functional roles of genes whose expression is modulated by potent acid inhibition may 
give new insight into the biological responses to this very common therapeutic 
intervention, including the mucosal response to the moderately increased gastrin 
levels encountered in clinical practice. 
Key words: cDNA microarray, gastrin, proliferation, esomeprazole, proton pump 
inhibitors   
3Introduction
The introduction of potent drugs (H2-blockers and proton pump inhibitors) in the 
1970s and 1980s for the control of gastric acid secretion completely changed medical 
therapy of peptic ulcer and reflux esophagitis. Maintenance therapy with proton pump 
inhibitors is widely used for patients with gastroesophageal reflux disease. In this 
patient group, long-term therapy is often used, as an alternative to surgery, to reduce 
the risk of complications from long-standing inflammatory and erosive processes like 
strictures, ulcers and bleeding. During the last decade, H2-blockers have been largely 
replaced by proton pump inhibitors which, by inhibiting the enzyme responsible for 
the final step in acid secretion (18), can virtually extinguish acid secretion.
The profound hypoacidity induced by proton pump inhibitors results in significant 
changes in the intragastric environment. Colonization of the stomach by bacteria 
which catalyze nitrosation may occur (70), with formation of potentially carcinogenic 
N-nitroso compounds (47). Also, the barrier function of acid against microorganisms 
and possibly prions is reduced (43, 53). Secondary to this, the immune and 
inflammatory responses in the mucosa are affected. With an increased pH, it is 
reasonable to believe that the cellular stress response of the gastric mucosa is 
changed. Administration of proton pump inhibitors reduces the feedback inhibition of 
acid on the synthesis and release of the acid secretagogue hormone gastrin, leading to 
increased serum gastrin in these patients (77). Gastrin stimulates acid secretion via the 
release of histamine from the enterochromaffin-like (ECL) cell (62). In addition to a 
specific and pronounced effect on function and proliferation of ECL cells, gastrin 
stimulates growth in the oxyntic mucosa (17, 24). It is not clear whether this general 
4trophic effect of gastrin is due to a direct action on the endodermal-derived stem cell 
or whether it is mediated indirectly by histamine, regenerating gene protein (Reg) or 
other substances released from the ECL-cell. In rats, long-term hypergastrinemia 
induced by very high doses of PPI’s not only increases mucosal thickness and the 
ECL cell density, but also results in the development of gastric carcinoids (17, 24). 
ECL cell hyperplasia, which is regularly found during the first year of omeprazole 
treatment in the rat, has also been reported in patients on proton pump inhibitor 
treatment (16), and carcinoid tumors have been seen in patients with hypergastrinemia 
induced by gastrin-producing tumors or atrophic gastritis (20). It is, however, debated 
whether carcinoid tumors may occur in humans in response to therapeutic acid 
inhibition.
There is only a very limited knowledge of the gene expression changes involved in 
the complex physiological and patophysiological responses to acid inhibition. The 
ECL-cells’ response to PPI-induced hypergastrinemia is reflected by increased 
abundance of histidine decarboxylase (Hdc) and Chromogranin A (CgA) mRNA (13, 
14). Moreover, both chronic and short-term hypergastrinemia stimulate gene 
expression and protein level of regenerating gene protein (Reg) in the fundic mucosa 
(45). However, ECL cells only represent a small fraction of the different exocrine and 
neuroendocrine cells present in gastric glands. Among the exocrine cells we find 
surface mucous cells, isthmus and neck cells, acid secreting parietal cells and 
pepsinogen secreting chief cells. The neuroendocrine cells, which constitute about 2% 
of the cells in the gastric mucosa, comprise ECL cells, which produce and release 
histamine, D cells (somatostatin), G cells (gastrin) and other neuroendocrine cells.
5Thus, only a few genes responsive to acid inhibition have been identified and 
characterized, and a more global gene discovery approach will most likely identify 
novel genes responsive to this pharmacological intervention. In a previous study, we 
identified genes differentially expressed in response to the PPI omeprazole in gastric 
mucosa of rats (51). In the present study, we have used DNA-microarray technology 
to investigate changes in the transcriptional profile of the oxyntic mucosa during a 
three-month treatment course with the PPI esomeprazole given to patients with reflux 
esophagitis in an ordinary therapeutic dose. The objective of this work was to see 
whether this very common clinical intervention induces significant changes in the 
mucosal gene expression pattern, especially with regard to cellular proliferation in the 
gastric mucosa. Using cDNA microarrays of 5346 genes, we show that esomeprazole 
modulates many genes not previously known to respond to acid inhibition, including 
genes involved in proliferation, apoptosis and stress response. 
6Materials and methods
Patients. The study was approved by the local Institutional Review Board. The 
patients had typical symptoms of gastroesophageal reflux disease, and were enrolled 
from those admitted to the Gastrointestinal Endoscopy Laboratory at St. Olav’s 
University Hospital for diagnostic upper endoscopy. Written, informed consent was 
obtained. The patients all had endoscopic signs of reflux esophagitis (degree 2 or 3 
according to the Savary Miller classification), and were treated with 40 mg 
esomeprazole (Nexium, Astra AB, Gothenburg, Sweden) once daily for 90 days. 
Before the study period 5 biopsy specimens were taken from the oxyntic mucosa at 
the major curvature, using a FB-13K E biopsy foreceps (Olympus, Japan). One of the 
specimens was preserved on formaline. The rest of the specimens were preserved in 
RNAlater buffer (Ambion, Austin, TX). During the last week of the study period 4 
biopsy specimens were taken from the same site. These specimens were all preserved 
on RNAlater buffer. Fasting blood samples were taken before and during the last 
week of the study period for gastrin measurement. 
Serum measurements.  Radioimmunoassay for gastrin and chromogranin A (CgA) was 
done as previously described (35, 71). Mean values ± SEM were calculated and the 
significance of the differences was evaluated by Wilcoxon matched pairs test. P<0.05 
was considered statistically significant. An ELISA assay (QUANTA Lite™ H. pylori 
IgG; INOVA Diagnostics, Inc., San Diego, CA) was performed in order to detect 
antibodies against Helicobacter pylori.
7Northern blot analysis. Northern blot analyses were performed for CgA, Gapdh and 
18S ribosomal RNA as previously described (5, 22, 72). A fragment of human 
histidine decarboxylase (Hdc) cDNA was generated by RT-PCR of total RNA from 
the promyelocytic leukaemia cell line HL-60 using primers corresponding to the 
1188-1205 and 1782-1799 stretches of the published (NM_002112) cDNA sequence 
of human histidine decarboxylase, with subsequent cloning of the fragment into the 
pCRII vector (Invitrogen, San Diego, CA, USA). The authenticity of the probe was 
verified by sequencing using standard methods. The significance of the differences 
was evaluated by Wilcoxon matched pairs test. P<0.05 was considered statistically 
significant.
RNA isolation. The specimens were homogenized in lysis buffer RLT provided in the 
RNeasy kit of Qiagen (Basel, Switzerland) and total RNA extracted using RNeasy  
according to the manufacturer’s protocol. Total RNA was further purified using the 
TRIzol method (phenol-guanidinium-thiocyanate) (GIBCO BRL Life Technologies, 
New York, NY), and examined for degradation by agarose electrophoresis with 
evaluation of the 18S and 28S ribosomal RNA bands. There was no degradation in 
any of the samples used for microarray analysis.
Microarray procedures. Microarrays were obtained from The Norwegian Microarray 
Consortium (www.microarray.no, Norway). Briefly, 6262 plasmids with sequence 
verified human probes were obtained from Research Genetics  (Huntsville, AL), 
amplified by PCR with M13 plasmid primers, purified by ethanol precipitation and 
analysed by agarose electrophoresis and redissolved in 50% DMSO at 0.05-0.50 
mg/ml. Probes were printed in duplicate onto amino-silane coated glass slides 
8(Corning CMT-GAPS; Corning, Corning, NY) using a MicroGrid II printing robot 
(BioRobotics; Cambridge, UK). The complete list of gene probes is deposited in the 
Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and is 
accessible through GEO Series accession number GSE3240. Ten different cDNAs 
from Arabidopsis thaliana (Stratagene Spotreporter; La Jolla, CA) were included in 
all arrays. Each Arabidopsis spike was printed 12 or 13 times on each array. 
Arabidopsis mRNA (Stratagene SpotReporter) was added to the samples prior to 
labeling and hybridization and was used as controls of the performance of the analysis 
with respect to labeling and hybridization efficiency.
Total RNA from patients before and during esomeprazole treatment (2 µg each), were 
reverse transcribed and labelled with Cy3- and Cy5-attached dendrimer, respectively, 
using the Genisphere 3DNA submicro dendrimer kit (Genisphere, Montvale, NJ) as 
described in the manufacturer’s protocol. The slides were pre-hybridized in 1% BSA, 
3.5x SSC, 1% SDS at 65oC for 20 min, then washed by dipping 5 times in deionized 
sterile filtered H2O, 2 times in isopropanol and air dried. Hybridization was done in a 
humidified hybridization chamber (Corning) at 60 oC for 18 h using 0.25 M NaPO4, 1 
mM EDTA, 4.5% SDS, 1x SSC, 2x Denhardt's solution and 0.2 µg human COT1 
DNA (GIBCO BRL Life Technologies), in a total hybridization volume of 35 µl. 
Post-hybridization washes were done for 15 min at 55oC with 2x SSC and 0.2% SDS, 
for 15 min at room temperature with 2x SSC and finally for 15 min at room 
temperature with 0.2x SSC. The arrays were scanned with a ScanArray Express HT 
scanner (Packard BioScience, Billerica, MA).
9Data analysis – filtering and normalization. The microarrays were analyzed using 
MicroArray Suite software version 2.1 (Scanalytics, Inc., Fairfax VA) with default 
settings. All subsequent statistical analyses were performed using the statistical 
package R (59). A signal to noise ratio based criterion was applied to remove the 
spots with spot intensity vs. background intensity ratio less than one in either channel. 
A spot area based criterion was applied to remove the spots with the area less than 10 
pixels in either channel. Print tip-dependent lowess normalization was applied to the 
data in order to compensate for systematic errors (84). The normalized ratio of the 
duplicates was averaged. Further analysis was done on the log2 transformed ratios. A 
gene was considered undetected and not tested, if the averaged ratio was missing on 
more than 50% of the microarrays.
Statistical Analysis. Statistically significant effects (up- or downregulation) of 
esomeprazole treatment were found using a two-sided one-sample Student’s t-test 
separately for each gene. Genes with P values less than 0.01 were considered 
statistically significantly regulated by esomeprazole treatment. To account for 
multiple testing we calculated adjusted P values controlling the False Discovery Rate 
(FDR) using the Benjamini-Hochberg (6) procedure.
Database submission of Microarray Data. The microarray data were prepared 
according to Minimum Information About a Microarray Experiment (MIAME) 
recommendations (8), have been deposited in NCBIs Gene Expression Omnibus 
(GEO, http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO Series 
accession number GSE3240.
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Histology and immunohistochemistry. For general histology, the formaline-fixed 
material was processed using routine histopathological procedures and stained with 
hematoxylin-eosin before examination by an experienced pathologist. For 
immunohistochemistry, tissue samples from the oxyntic mucosa were taken from 
corpus/fundus region and immersed in 4% phosphate-buffered formaldehyde and 
dehydrated in 80% ethanol before paraffin embedding. From paraffin blocks, 4 µm 
sections were cut and deparaffinised with xylene, rehydrated and treated with 3% 
hydrogen peroxide for 10 minutes to block endogenous peroxidase activity. Antigen 
retrieval was achieved by heating the slides immersed in Tris-EDTA buffer pH 9.1 
(Hdc and urokinase (Plau)) or in citrate buffer pH 6.0 (H+/K+ATPase and NF-B
(p50)) in a commercial microwave oven at 160 W for 15 minutes. Antibodies against 
rat Hdc (1:5000, Eurodiagnostica, Malmö, Sweden), NF-B (p50) (1:200, Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA), H+/K+ATPase (1:1000, Affinity Bioreagents, 
Golden, CO) and urokinase (Plau) (1:10, Cell Sciences Inc., Canton, MA) were 
diluted in Tris-buffered saline pH 7.4 with 0.025% Tween 20 (DakoCytomation, 
Glostrup, Denmark) and 1% bovine serum albumin (Sigma, St. Louis, MS), and the 
sections were incubated with antibodies for 60 minutes. The immunoreactions were 
visualised using an EnVision-HRP kit (K5007, DAKO, Glostrup, Denmark) and AEC 
peroxidase kit (SK4200, Vector, Burlingame, CA) or Vector SG (SK4700, Vector, 
Burlingame, CA).
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Results
Patient characteristics. Eight patients were included in the study, 3 female (aged 44-
70, median 54 years) and 5 male (33-72 years, median 42 years). All had endoscopic 
signs of reflux esophagitis, degree 2 or 3 according to the Savary Miller classification 
prior to esomeprazole treatment. At the 3-month control endoscopy the esophageal 
lesions were completely healed in all patients, indicating a clinically effective acid 
inhibition. Measurements of serum gastrin and CgA were available for seven of eight 
patients. Average serum gastrin before treatment was 4±1 pM (n=7) (mean±SEM), 
and after 90 days treatment with esomeprazole 20±3 pM (n=7) (mean±SEM) 
(P=0.0156). Average serum CgA before treatment was 18 ±4 ng/ml (n=7) 
(mean±SEM), and after 90 days with esomeprazole 33±5 ng/ml (n=7) (mean±SEM) 
(P=0.0156). Northern blot analyses of Hdc and CgA were available for all patients. 
Both Hdc and CgA mRNA expression increased (P=0.039) during treatment. Thus, 
esomeprazole induced a significant increase in serum gastrin, Hdc and CgA. This is in 
accordance with previous results (78). Histopathological examination showed gastritis 
in one of the patients. The same patient was infected by H. pylori and had the highest 
levels of gastrin and CgA. None of the other patients were infected by H. pylori and 
the gastric mucosa showed normal histology. 
Genes differentially regulated in response to esomeprazole treatment. Genes 
differentially expressed in response to esomeprazole were identified by microarray 
analysis by hybridization of RNA from a patient before esomeprazole treatment 
against RNA from the same patient during esomeprazole treatment. We found that 
149 genes exhibited changed expression levels (P<0.01) in patients treated with the 
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proton pump inhibitor for 3 months. Of these, 56 (38%) were induced and 93 (62%) 
were repressed. The False Discovery Rate (FDR) was estimated to be 10%. i.e. we 
expect on the average that 10% of the genes called significantly differentially 
regulated by esomeprazole treatment are false positives. The list of all 149 genes is 
shown in Supplemental Table S1 (available at the Physiological Genomics web site).1
To facilitate interpretation of the results, genes with changed expression in response to 
esomeprazole were grouped according to cellular processes in which they are likely to 
be involved, based on information from the literature and from the Norwegian 
Microarray Consortium Annotation Database (www.microarray.no) (Table 1). All genes 
regarded to be involved in the processes proliferation, apoptosis, stress, inflammatory 
and immune response are listed in Table 1. We chose to focus on these processes 
because they were considered to be the most interesting ones in the molecular 
response to acid inhibition. Of the 149 differentially expressed genes, 72 (48%) could 
be classified into these broad functional groups. Mediators of proliferation and 
apoptosis comprised the largest functional gene cluster (60 genes, 40%), whereas the 
numbers of genes involved in immune/inflammatory responses (33 genes, 22%) and 
stress response (32 genes, 21%) were somewhat lower. Several genes were involved 
in more than one of these biological processes (Table 1). Relatively, most annotations 
were found for the upregulated genes. This phenomenon has also been observed by 
others (30).
Validation of results by Exogenous RNA Spikes. Validation of our microarray protocol 
was done using the SpotReport Array Validation System (Stratagene). Analysis of 
exogenous (A. thaliana) mRNA spiked into labeling reactions at predetermined ratios 
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showed that the observed ratios highly correlated with the expected ratios (the median 
across arrays for the pairwise correlation of all observed RNA control spots ratios 
with expected ratios was 0.90) The observed RNA control spots were also highly 
correlated across experiments (median correlation of all observed RNA control spots 
for pairs of arrays of 0.96). The expected ratios for the RNA controls were 6, 5, 4, 3, 
2, 1, 0.5, 0.33, 0.25, and 0.125. The external controls showed that a twofold change in 
mRNA levels could be reliably detected and correlated well with expected fold 
changes. However, the observed fold changes for the external controls were 
underestimated at both ends of the expected range (data not shown). This is similar to 
our observations in previous studies (51, 83). 
Further verification of results using Northern Blot, semi-quantitative RT-PCR and 
real-time quantitative RT-PCR has previously shown that the false positives in our 
studies are within the range commonly found in microarray experiments (10, 26, 51, 
52, 65, 83).
Sequencing. Errors in the IMAGE collections have been reported, and additional 
errors may have occurred during production. For this reason, 39 (26%) of the clones 
representing genes regarded as the most interesting, were sequence verified using 
standard methods. Good sequencing results were obtained for 27 of the clones and 21 
(78%) of these showed the expected sequence. For 6 of the 27 clones the sequence 
was wrong. The incorrect clones were shown to represent a different gene than 
expected. The new gene information is reported in Table 1 and Supplemental Table 
S1 (Supplemental Table S1 is available at the Physiological Genomics web site1). 
Three of the incorrect clones (IMAGE nr 898109, 770858 and 360885) were shown to 
represent genes (Ttc1, Gnai1, and Comm6) already present in the list of differentially 
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expressed genes. Hence, these clones were removed from the table. Notably, for all 
three genes, both clones were found to be regulated in the same direction.
Rat Orthologs. In a previous study, we identified differentially expressed genes in 
gastric mucosa of omeprazole-dosed rats (51). In the present study, we tried to find rat 
orthologs for the 39 sequenced human genes. Rat orthologs were found for 37 of these 
39 genes. 17 of the genes were found to have rat orthologs present on the rat arrays 
used. Notably, eight of these genes were found to be regulated in the same direction in 
rat and man in response to omeprazole/esomeprazole, although the omeprazole 
induction of rat genes was not found to be statistically significant, and hence not 
reported in the previous article. All eight genes are listed in Table 2.
Immunohistochemistry. The Hdc immunoreactive cells were found in the basal half of 
the glands (Fig. 1A). Some of the cells were seen with cytoplasmatic extensions (Fig. 
1A, inset). The distribution and shape of these cells are characteristic of 
neuroendocrine cells of the oxyntic mucosa. Urokinase (Plau) immunoreactivity was 
seen in cells shaped and distributed like parietal cells (Fig. 1B). NF-B (p50) 
immunoreactivity was only seen in the nucleus of H+/K+ATPase immunoreactive cells 
(Fig. 1C). Co-localisation to H+/K+ATPase immunoreactive cells indicates that NF-B 
is located to parietal cells.
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Discussion
In the present study, molecular responses in gastric mucosa of patients treated with 
the proton pump inhibitor esomeprazole were studied by measuring genome-wide 
transcript level changes using cDNA microarrays with probes representing 5346 
genes. The acid inhibitory treatment with esomeprazole was clinically effective, as 
evidenced by the complete healing of esophageal lesions in all patients. Fasting serum 
gastrin and the serum concentration of CgA changed as expected, with significant 
increases within the range of normal values. In a previous study from our laboratory 
(78), treatment for a comparable period of time with an equivalent drug (omeprazole) 
showed a similar fasting serum gastrin and CgA response. In that study, histamine and 
CgA increased in tissue biopsies confirming that ECL cell stimulation takes place 
during therapeutic acid inhibition. Furthermore, multiple measurements of serum 
gastrin in each patient with area-under-curve calculations showed that the 24-h gastrin 
exposure is far higher during PPI treatment than is reflected by a single fasting gastrin 
measurement. Thus, the gastrin exposure of the gastric mucosa in this study is much 
more pronounced than suggested by the relatively modest increase in fasting serum 
gastrin. 
The genes encoding CgA and Hdc, both known to be induced by gastrin, (13, 14), 
showed significantly elevated transcript levels during treatment with esomeprazole 
(data not shown). Because gene probes for these two genes were not present on the 
microarrays (Hdc), or were filtered away during the quality control (CgA), these 
measurements were performed by Northern blot. These results show that a gene 
expression response to gastrin was obtained in the study patients, and confirm earlier 
observations on gene expression changes of gastric mucosa in response to acid 
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inhibition. Results from a previous study from our laboratory indicate that microarray 
analysis can indeed be used to detect gene expression changes in a minor cell 
population of the complex gastric tissue such as ECL cells (51).
Of the 149 genes identified as differentially expressed, 39 were tested for rat 
orthologs. 17 of the tested 39 differentially expressed human genes were found to 
have rat orthologs present on the rat arrays used in our previous study on omeprazole-
dosed rats. Notably, eight of these genes were found to be regulated in the same 
direction in rat and man in response to omeprazole/esomeprazole. All eight genes are 
listed in Table 2. Among these genes, it is interesting to find the upregulated genes 
plasminogen activator, urokinase (Plau) and BCL2-related Mcl1. Plau expression is 
known to correlate with tumor angiogenesis and poor outcome in gastric cancer (31). 
Mcl1 is known to be upregulated in response to IL-6 in the human gastric cancer cell 
line AGS (41). The gene Kruppel-like factor 4 (gut) (Klf4) was downregulated in 
response to acid inhibition. Highly interesting, Klf4 is known to repress expression of 
Hdc (1). Decreased expression of this gene has been shown to be critical in 
development and progression of gastric carcinoma (80). All eight genes are annotated 
to one or more of the biological processes discussed below.
The 149 genes found to be differentially regulated in esomeprazole-treated patients 
are most likely directly or indirectly regulated by acid inhibition and/or 
hypergastrinemia. The functional diversity of the candidate genes suggests that many 
of them are likely to be differentially regulated as indirect consequences of the many 
processes affected by PPI’s in gastric mucosa. One particularly interesting 
downregulated gene is radixin (Rdx), which has been suggested to be involved in 
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secretion of gastric acid (74). The present study is the first to report that expression of 
radixin is reduced in response to treatment with acid inhibitors. Another interesting 
gene, the upregulated cytochrome c oxidase subunit Va (Cox5a) has been suggested 
as a diagnostic marker for gastric carcinoma (50).
Since gastrin is known to stimulate proliferation of both the ECL-cells and the gastric 
mucosa in general, genes involved in this process were regarded as the most 
interesting. The immune/inflammatory cellular processes are also of great interest, 
since for instance Helicobacter pylori infection of the human stomach is very 
common, and related to various diseases such as gastritis, peptic ulcer, mucosa-
associated lymphoid tissue (MALT) lymphomas and gastric cancer. The 
immune/inflammatory processes are most likely affected by the dramatic changes in 
the intragastric environment induced by potent acid inhibition. Moreover, with an 
increased pH, there is also reason to believe that the cellular stress response of the 
gastric mucosa is changed. In the following, these selected processes and the genes 
involved will be discussed.
Proliferation and apoptosis. Not surprisingly, mediators of proliferation and apoptosis 
comprised the largest functional gene cluster (Table 1). This finding is similar to 
results from our previous microarray study on omeprazole-dosed rats (51), although 
we report mostly different genes due to the low number of differentially expressed 
genes common to both arrays. Hypergastrinemia induced by potent and longterm 
inhibition of gastric acid secretion increases proliferation rate and mucosal tickness 
(17, 24). Apoptosis normally plays a role complementing proliferation and is 
considered to be essential for the maintenance of gastro-intestinal homeostasis and 
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health (58). Disturbance in the balance between these two processes may predispose 
to cell loss with mucosal damage or cell accumulation and cancer development (33, 
85). In the normal gastric mucosa, approximately 1-3% of gastric epithelial cells in 
the antrum or corpus/fundus are apoptotic (61). The present study indicates an 
increased proliferation and decreased apoptosis in response to inhibition of gastric 
acid secretion and identifies genes possibly involved in these processes.
An enrichment of genes accosiated with proliferation and apoptosis was found for 
upregulated genes. Overproduction of tumor supressor p53, which is upregulated in 
the present study, has previously been shown in the ECL-cells during 
hypergastrinemia in the African rodent mastomys (42). Moreover, the plasminogen 
activator, urokinase (Plau), is known to stimulate proliferation and has previously
been implicated in gastric carcinoma (15, 31). Most of the upregulated genes in this 
category are involved in positive regulation of cell proliferation  (e.g. prostate tumor 
over expressed gene 1 (Ptov1) (63), tripeptidyl peptidase II (Tpp2) (69), 
minichromosome maintenance deficient 3 (Mcm3) (21), and GRB2-associated binding 
protein 1 (Gab1) (9)). A remarkably high number (13 genes, 23%) of upregulated 
genes have been reported to have anti-apoptotic effects. In this group we find 
tripeptidyl peptidase II (Tpp2) (69), presenilin 1 (Psen1) (3), brain and reproductive 
organ-expressed (Bre) (39), plasminogen activator, urokinase (Plau) (76), and BCL2-
related gene Mcl1 (41). Furthermore, Act1 (C6orf4) activates the anti-apoptotic 
transcription factor NF-B, which is constitutively activated in human gastric 
carcinoma tissue (64, 82).
Among the downregulated genes, we found hydroxysteroid (17-beta) dehydrogenase 
13 (Sdcr9), the E2F transcription factor 4 (E2f4), transcription factor Klf4, tumor 
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supressor Rbl2, and the ras homolog gene family member B (Rhob) which are all 
known to be negative regulators of cell proliferation (11, 38, 40, 54, 57). Rhob may 
also play a role in induction of apoptosis (57). Several others of the downregulated 
genes are also known to induce apoptosis. Among these are Hmga2 (56), calreticulin 
(Calr) (44), the tumor supressor gene cylindromatosis (Cyld) (79), protein kinase C 
zeta (Prkcz) (19), and protein kinase c-like 2 (Pkn2) (32). 
The fact that a remarkably high number of the differentially expressed genes are 
involved in proliferation and/or apoptosis supports our hypotesis that there is a 
significant change in cell turnover during chronic administration of PPI. The 
expression patterns of positive and negative regulators of proliferation and apoptosis 
indicate a complex involvement of the identified genes in increased proliferation and 
decreased apoptosis, inducing the mucosal hyperplasia. However, the complexity of 
the gastric mucosa makes precise interpretation of these results difficult. Numerous 
studies report that gastrin stimulates proliferation of both the ECL-cells and the 
gastric mucosa in general, the effect on ECL cells being more pronounced than the 
general trophic effect (4, 17, 24). The growth-related genes found here represent good 
candidates for further confirmation and follow-up studies that may shed light on the 
precise cellular molecular responses to potent acid inhibition.
Stress responses.  Of 149 differentially expressed genes with known function, 32 
encode proteins involved in stress responses.  This observation is in agreement with 
the findings in our previous study on omeprazole-dosed rats (51). Several markers of 
stress response were significantly reduced during acid inhibition. Prolactin (Prl) (86), 
brain-derived neurotrophic factor (Bdnf) (2), the general transcription factor II, I 
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(Gtf2i) (55), glutathione-S-transferase-like protein (Gsto1) (37) and heat shock protein 
Hsph1 (23) are all downregulated in response to acid inhibition. Downregulation of 
stress responsive genes may be due to the decreased level of gastric acid in the 
stomach. Gastric acid is the main aggressive factor in the intragastric environment and 
a prerequisite for disorders like peptic ulcer disease, stress ulcer and ulcerative 
gastritis. On the other hand, the success of pharmacological treatment to prevent or 
heal ulcerative lesions may not depend only on the blockade of acid secretion, but also 
on the enhancement of mucosal protective factors. Antioxidant depletion is belived to 
be a mechanism involved in the pathophysiology of several upper gastrointestinal 
disorders, and H+/K+-ATPase inhibitors can alter free radical production by 
neutrophils. Esomeprazole has been shown to be protective against oxidative stress 
due to its antioxidant properties (36). It is therefore interesting to note that the 
upregulated genes paraoxonase 1 (Pon1), fatty acid binding protein 5 (Fabp5), 
myeloid cell leukemia 1 (Mcl1) and selenophosphate synthetase 1 (Seph5) all are 
belived to be involved in the protection agains oxidative stress (7, 29, 46, 66).  
Moreover, inhibition of the downregulated gene encoding calreticulin (Calr) has been 
shown to enhance cytoprotection against oxidative stress (28). These proteins may be 
involved in the molecular mechanisms underlying acid-independent gastroprotective 
effects of proton pump inhibitors. 
Inflammatory and immune responses. Altered gene expression was observed for 
surprisingly many genes known to be involved in immune and inflammatory 
responses. Many of these were upregulated. Patients with reduced gastric acidity are 
more susceptible to bacterial infections with enteropathogenic bacteria. The high 
number of genes involved in these processes may be due to gene expression in 
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immune cells infiltrating into the gastric mucosa. Examples of such genes are formyl 
peptide receptor 1 (Fpr1) (12), Interleukin 17 receptor B (Il17rb) (67) and interferon-
stimulated transcription factor 3 (Isgf3g) (48). Reducing the amount of acid with 
potent proton pump inhibitors may also reduce inflammatory responses in the gastric 
mucosa since gastric acid is the main aggressive factor in the intragastric 
environment. Downregulation of chemokine (C-C motif) ligand 2 (Ccl2), interleukin 
4 receptor (Il4r), Cd58 and matrix metalloproteinase 7 (Mmp7) which all are involved 
in immune and/or inflammatory responses, may be interpreted to indicate that these 
proteins may be involved in protecting the gastric mucosa against acid-induced 
damage (34, 60, 75, 81). The downregulated gene product of prostaglandin E receptor 
3 (Ptger3) and ATP-binding cassette, sub-family B (MDR/TAP), member 1 (Abcb1) 
are shown to play a central role in adaptive cytoprotection and host- bacterial 
interactions, respectively, in the gastrointestinal tract (25, 73). Gastric parietal cells 
are known to express Ptger3 mRNA (73).
The gastric mucosa is very complex, with intermingling cells of different types with 
various roles in the acid secretory process. Parietal cells comprise about 32% of the 
corpus mucosa, whereas chief cells make up about 26%. The remainder of the gastric 
mucosal cells comprise about 17% surface mucous cells, 6% mucosal neck cells, and 
20% lamina propria cells (27). Endocrine cells constitute about 2% of the cells in the 
gastric corpus region and mainly belong to one of the following types: ECL cells 
(35%), EC cells (25%) and somatostatin (D) cells (26%). The remaining 14% consists 
of A-like cells, D1 cells and P cells (68). The present experiment gives a picture of the 
gene expression changes in the total cell population of the gastric mucosa, and must 
be followed by further analysis using other methods, like single-cell studies, 
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immunohistochemistry or in situ hybridization, to identify the cell types in which 
genes of interest are expressed. Thus, some of the differentially expressed genes, 
chosen to cover several biological functions, were studied further by 
immunohistochemistry. Plasminogen activator urokinase (Plau) encodes a serine 
protease involved in degradation of the extracellular matrix and possibly tumor cell 
migration and proliferation (15). This protein converts plasminogen to plasmin and is 
most likely localized to parietal cells. Localization of NF-B to the nucleus of 
H+/K+ATPase immunoreactive cells indicates that NF-B is located to parietal cells. 
This anti-apoptotic transcription factor has been shown to be activated by the 
upregulated transcription factor Act1 (C6orf4) (82). NF-B is known to be expressed 
in parietal cells (49). Since the ECL cell is an undisputed target of gastrin, staining for 
ECL cell Hdc was done and as shown in the figure neither Plau nor NFB is 
expressed in this cell type.
Inhibitors of gastric acid secretion are among the most commonly used drugs in 
clinical practice. In the present study, a comprehensive set of candidate genes not 
previously associated with acid inhibition was revealed, which underlines the complex 
nature of this therapeutic intervention. Our results indicate a global change in the 
induction of proliferation, apoptosis, inflammatory, immune and stress response in the 
presence of proton pump inhibitors. The genes presented in the present study are 
likely to be associated with acid inhibition. Further studies specifically targeting the 
genes implicated in this study will further our understanding of the molecular 
responses to potent acid inhibition, including the mucosal response to moderately 
increased gastrin levels encountered in clinical practice.
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Text footnotes
1
 The Supplemental Table S1 is available online at 
http://physiolgenomics.physiology.org
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Table 2 Differentially expressed genes in esomeprazole-treated patients that are 
found to have rat orthologs previously shown to be similarily regulated in 
omeprazole-dosed rats.
CloneNo Unigene 186 
Cluster
Gene name Symbol
Upregulated
714106 Hs.77274 Plasminogen activator, urokinase Plau
843287 Hs.532826 Myeloid cell leukemia sequence 1 (BCL2-related) Mcl1
Downregulated
504763 Hs.252189 Syndecan 4 (amphiglycan, ryudocan) Sdc4
167280 Hs.496255 Protein kinase C, zeta Prkcz
768370 Hs.502876 Ras homolog gene family, member B Rhob
188232 Hs.376206 Kruppel-like factor 4 (gut) Klf4
548957 Hs.278589 General transcription factor II, i Gtf2i
752732 Hs.371914 Bleomycin hydrolase Blmh
Paper V

Supplemental Table S1. A full list of differentially regulated genes in esomeprazole-treated patients.
CloneID Unigene 186 Cluster Name Symbol P value Mean Ratio SD
Upregulated genes, P<0.01
81599* Hs.464416 ubiquitin specific protease 14 (tRNA-guanine transglycosylase) Usp14 0,001 1,2 0,1
207370 Hs.80720 GRB2-associated binding protein 1 Gab1 0,001 1,2 0,1
725223 Hs.413801 Proteasome (prosome, macropain) activator subunit 4 Psme4 0,001 1,4 0,1
124795 Hs.461453  WW domain containing oxidoreductase Wwox 0,001 1,9 0,5
843287* Hs.532826 myeloid cell leukemia sequence 1 (BCL2-related) Mcl1 0,001 1,6 0,4
809557 Hs.179565 minichromosome maintenance deficient (S. cerevisiae) 3 Mcm3 0,001 1,6 0,2
296094 Hs.50308 Huntingtin interacting protein 2 Hip2 0,001 1,3 0,1
235924 Hs.233552 Cell division cycle 2-like 5 (cholinesterase-related cell division controller) Cdc2l5 0,002 1,3 0,2
783849 Hs.86724 GTP cyclohydrolase 1 (dopa-responsive dystonia) Gch1 0,002 1,1 0,1
840702§ Hs.124027  Selenophosphate synthetase 1 Sephs1 0,002 1,6 0,4
840702§ Hs.528583 Similar to selenophosphate synthetase 0,002 1,6 0,4
681948 Hs.196981 Nasopharyngeal carcinoma, down-regulated 1 Fhit 0,003 1,5 0,4
81331§ Hs.530733 Syntaxin 3A Stx3a 0,003 1,9 0,6
81331§ Hs.408061 Fatty acid binding protein 5 (psoriasis-associated) Fabp5 0,003 1,9 0,6
136821† Hs.1706 Interferon-stimulated transcription factor 3, gamma 48kDa Isgf3g 0,003 1,5 0,3
753620* Hs.274313 insulin-like growth factor binding protein 6 Igfbp6 0,003 1,5 0,3
810372 Hs.32942 phosphoinositide-3-kinase, catalytic, gamma polypeptide Pik3cg 0,003 2,2 1,0
138745 Hs.28426 Transcribed locus  0,003 1,1 0,0
789011 Hs.83347 angio-associated, migratory cell protein Aamp 0,003 1,5 0,4
45556 Hs.35828 MAP/microtubule affinity-regulating kinase 3 Mark3 0,004 1,8 0,4
544664 Hs.268939 matrin 3 Matr3 0,005 1,4 0,3
307882 Hs.291212 tubulin-specific chaperone a Tbca 0,005 1,5 0,4
773236* Hs.753 formyl peptide receptor 1 Fpr1 0,005 1,4 0,3
714106 Hs.77274 plasminogen activator, urokinase Plau 0,005 1,7 0,6
144924 Hs.486228 TRAF3 interacting protein 2 C6orf4 0,005 1,6 0,4
70489 Hs.120950 Rhesus blood group-associated glycoprotein Rhag 0,006 1,6 0,5
739993* Hs.258314 brain and reproductive organ-expressed (TNFRSF1A modulator) Bre 0,006 1,3 0,2
34773 Hs.506852 protein tyrosine phosphatase, non-receptor type 11 Ptpn11 0,006 1,5 0,4
727390* Hs.3260 presenilin 1 (Alzheimer disease 3) Psen1 0,006 1,5 0,4
133180 Hs.250648 Hypothetical LOC389188  0,006 1,4 0,3
128695 Hs.502100 Hypothetical protein FLJ90119 Flj90119 0,006 1,5 0,3
898281 Hs.195464 filamin A, alpha (actin-binding protein-280) Flna 0,006 1,7 0,5
725274 Hs.519718 tetratricopeptide repeat domain 1 Ttc1 0,007 1,5 0,4
843312 Hs.528305 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 17 (72kD) Ddx17 0,007 1,5 0,5
796253 Hs.533383 polymerase (RNA) II (DNA directed) polypeptide J (13.3kD) Polr2j 0,007 1,4 0,3
137736 Hs.176854 Hypothetical LOC401320 Loc401320 0,007 1,3 0,3
343352 Hs.507805 Component of oligomeric golgi complex 6 Cog6 0,007 1,3 0,1
67033 Hs.170205 Transcribed locus, mod. sim. to NP_001432.1 fatty acid amide hydrolase  0,007 1,2 0,1
838676 Hs.496593 calpain 6 Capn6 0,007 1,8 0,6
79688 Hs.515472 Small nuclear ribonucleoprotein D2 polypeptide 16.5kDa Snrpd2 0,008 1,6 0,5
824068 Hs.401903 cytochrome c oxidase subunit Va Cox5a 0,008 1,4 0,3
788566* Hs.80296 Purkinje cell protein 4 Pcp4 0,008 1,6 0,5
144802 Hs.49787 Latent transforming growth factor beta binding protein 1 Ltbp1 0,008 1,9 0,5
233783 Hs.136338 Interleukin 17 receptor B Il17rb 0,008 1,2 0,1
796542 Hs.43697 ets variant gene 5 (ets-related molecule) Etv5 0,008 1,7 0,5
293328* Hs.432438 Echinoderm microtubule associated protein like 4 Eml4 0,008 1,2 0,1
151251 Hs.239459 regulatory solute carrier protein, family 1, member 1 Rsc1a1 0,008 1,5 0,4
544639 Hs.95612 Desmocollin 2 Dsc2 0,008 1,4 0,4
128143* Hs.370995 paraoxonase 1 Pon1 0,008 1,1 0,1
24085 Hs.432424 tripeptidyl peptidase II Tpp2 0,008 1,9 0,6
24415* Hs.408312 tumor protein p53 (Li-Fraumeni syndrome) Tp53 0,009 1,6 0,3
840658 Hs.515540 prostate tumor over expressed gene 1 Ptov1 0,009 1,2 0,2
75254 Hs.530904 cysteine and glycine-rich protein 2 Csrp2 0,009 1,2 0,2
240637 Hs.40094 Leucine rich repeat containing 42 Mgc8974 0,009 1,4 0,4
248688 Hs.530473 Transcribed locus  0,009 1,5 0,3
40017§ Hs.437060 Cytochrome c, somatic  Cycs 0,010 2,1 0,6
40017§ Hs.511873  Transcribed locus, strongly similar to NP_061820.1 cytochrome c 0,010 2,1 0,6
782587 Hs.75275 Ubiquitination factor E4A (UFD2 homolog, yeast) Ube4a 0,010 1,7 0,6
814696 Hs.482497 Transportin 1 Tnpo1 0,010 1,4 0,4
Downregulated genes, P<0.01
303048 Hs.408073 ribosomal protein S6 Rps6 <0,001 0,8 0,0
210887 Hs.546303 suppression of tumorigenicity 13 (Hsp70-interacting protein) St13 <0,001 0,6 0,1
753211* Hs.445000 prostaglandin E receptor 3 (subtype EP3) Ptger3 <0,001 0,5 0,1
39127† Hs.530199 Ankyrin repeat domain 46 Loc157567 <0,001 0,7 0,1
813742§ Hs.90572 PTK7 protein tyrosine kinase 7 Ptk7 <0,001 0,6 0,1
813742§ Hs.460468 Exportin 6 Xpo6 <0,001 0,6 0,1
470368 Hs.517731 hypothetical protein PP2447 Pp2447 <0,001 0,6 0,1
222181 Hs.506759 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 Atp2a2 <0,001 0,8 0,1
768370*§  Hs.502876 ras homolog gene family, member B Rhob <0,001 0,6 0,1
753430 Hs.533526 alpha thalassemia/mental retardation syndrome X-linked Atrx <0,001 0,7 0,1
752732* Hs.371914 bleomycin hydrolase Blmh <0,001 0,5 0,2
280752*§ Hs.79362 retinoblastoma-like 2 (p130) Rbl2 <0,001 0,6 0,1
80946 Hs.12013 ATP-binding cassette, sub-family E (OABP), member 1 Abce1 0,001 0,8 0,1
381166 Hs.35758 MYST histone acetyltransferase (monocytic leukemia) 4 Myst4 0,001 0,8 0,1
469952 Hs.508266 COMM domain containing 6 Commd6 0,001 0,7 0,1
666829 Hs.387207 sarcoglycan, delta (35kD dystrophin-associated glycoprotein) Sgcd 0,001 0,5 0,2
293727 Hs.208912 Chromosome 22 open reading frame 18 C22orf18 0,001 0,7 0,1
282501 Hs.437174 solute carrier family 6 (neurotransmitter transporter), member 12 Slc6a12 0,001 0,8 0,1
823930 Hs.124126 actin related protein 2/3 complex, subunit 1A (41 kD) Arpc1a 0,001 0,8 0,1
154138 Hs.443490 membrane-bound transcription factor protease, site 2 Mbtps2 0,001 0,7 0,1
234331 Hs.458499 Ubiquitin specific protease 3 Usp3 0,001 0,8 0,1
166195 Hs.530687 Ribonuclease/angiogenin inhibitor 1 Rnh 0,001 0,8 0,1
668851 Hs.502182 brain-derived neurotrophic factor Bdnf 0,001 0,6 0,2
202535§ Hs.433391 metallothionein 1G Mt1g 0,001 0,5 0,2
202535§ Hs.556040 H19, imprinted maternally expressed untranslated mRNA H19 0,001 0,5 0,2
79502§ Hs.516157 methionine adenosyltransferase II, alpha Mat2A 0,001 0,8 0,1
79502§ Hs.506309 Early endosome antigen 1, 162kD Eea1 0,001 0,8 0,1
753215 Hs.134587 guanine nucleotide binding protein (G protein) Gnai1 0,002 0,5 0,2
591653† Hs.165830 Ecotropic viral integration site 1 Evi1 0,002 0,7 0,2
490368 Hs.34341 CD58 antigen, (lymphocyte function-associated antigen 3) Cd58 0,002 0,7 0,1
261204 Hs.505924 High mobility group AT-hook 2 Hmga2 0,002 0,7 0,2
740554 Hs.263671 radixin Rdx 0,002 0,6 0,1
504236 Hs.1905 prolactin Prl 0,002 0,7 0,1
343443 Hs.334587 RNA-binding protein gene with multiple splicing Rbpms 0,002 0,6 0,1
470393 Hs.2256 matrix metalloproteinase 7 (matrilysin, uterine) Mmp7 0,002 0,8 0,1
768357 Hs.458423 cerebellin 1 precursor Cbln1 0,002 0,6 0,2
548957*§ Hs.278589 general transcription factor II, i Gtf2i 0,003 0,7 0,0
188232* Hs.376206 Kruppel-like factor 4 (gut) Klf4 0,003 0,7 0,2
281904 Hs.529925 Ubiquitin protein ligase E3 component n-recognin 2 Ubr2 0,003 0,7 0,1
550355 Hs.440833 Protein kinase N2 Pkn2 0,003 0,8 0,1
245484§ Hs.160561  Similar to KIF27C Loc389765 0,003 0,9 0,1
245484§ Hs.545918 Transcribed locus 0,003 0,9 0,1
49344 Hs.35490 KIAA0350 protein Kiaa0350 0,003 0,7 0,2
138917 Hs.437922 V-myc myelocytomatosis viral oncogene homolog 1 Mycl1 0,003 0,7 0,1
46897 Hs.30954 phosphomevalonate kinase Pmvk 0,003 0,6 0,1
207255 Hs.361323 ATP-binding cassette, sub-family F (GCN20), member 3 Abcf3 0,003 0,6 0,2
714426 Hs.132370 cleavage stimulation factor, 3' pre-RNA, subunit 2, 64kD Cstf2 0,003 0,8 0,1
714453 Hs.513457 interleukin 4 receptor Il4r 0,004 0,8 0,1
592359 Hs.278721 Solute carrier family 39 (zinc transporter), member 7 Slc39a7 0,004 0,7 0,2
768561* Hs.303649 Chemokine (C-C motif) ligand 2 Ccl2 0,004 0,6 0,2
840493 Hs.78224 ribonuclease, RNase A family, 1 (pancreatic) Rnase1 0,004 0,7 0,2
156045 Hs.200600 Secretory carrier membrane protein 3 Scamp3 0,004 0,8 0,2
485858 Hs.391781 protocadherin 20 Pcdh20 0,004 0,8 0,1
824704 Hs.75694 mannose phosphate isomerase Mpi 0,004 0,9 0,1
48614* Hs.271940 E74-like factor 4 (ets domain transcription factor) Elf4 0,004 0,6 0,2
296529 Hs.160976 SA hypertension-associated homolog (rat) Sah 0,004 0,8 0,1
668182 Hs.100921 zinc finger protein 193 Znf193 0,005 0,8 0,1
136382 Hs.432993 Cylindromatosis (turban tumor syndrome) Cyld 0,005 0,8 0,1
813256 Hs.489033 ATP-binding cassette, sub-family B (MDR/TAP), member 1 Abcb1 0,005 0,6 0,2
770794 Hs.521482 Src homology 2 domain containing adaptor protein B Shb 0,005 0,7 0,2
26021 Hs.463928 discs, large (Drosophila) homolog 4 Dlg4 0,005 0,7 0,2
815781 Hs.36927 Heat shock 105kDa/110kDa protein 1 Hsph1 0,005 0,8 0,1
767069 Hs.368592 Chromosome 11 open reading frame 32 Sorl1 0,005 0,6 0,1
842980 Hs.115242 developmentally regulated GTP-binding protein 1 Drg1 0,006 0,9 0,1
42558 Hs.75335 glycine amidinotransferase (L-arginine:glycine amidinotransferase) Gatm 0,006 0,7 0,2
470216 Hs.149387 myosin VI Myo6 0,006 0,7 0,2
167280§ Hs.496255 protein kinase C, zeta Prkcz 0,006 0,8 0,2
167280§ Hs.107101 Chromosome 1 open reading frame 86 C1orf86 0,006 0,8 0,2
363590 Hs.459070 aryl-hydrocarbon receptor nuclear translocator 2 Arnt2 0,006 0,8 0,2
32684 Hs.488171 NudC domain containing 3 Kiaa1068 0,006 0,8 0,1
28098 Hs.270869 Zinc finger protein 410 Znf410 0,006 0,8 0,1
262231 Hs.515162 Calreticulin Calr 0,006 0,8 0,2
199610 Hs.516243 Thrombospondin repeat containing 1 Tsrc1 0,006 0,8 0,1
504763* Hs.252189 syndecan 4 (amphiglycan, ryudocan) Sdc4 0,006 0,6 0,2
328591 Hs.73923 pancreatic lipase-related protein 1 Pnliprp1 0,006 0,7 0,2
33941 Hs.89655 protein tyrosine phosphatase, receptor type, N Ptprn 0,006 0,8 0,1
813552 Hs.446414 CD47 antigen (Rh-related antigen, integrin-associated signal transducer) Cd47 0,006 0,8 0,2
46518 Hs.58919 dystrobrevin, alpha Dtna 0,007 0,8 0,2
83120 Hs.401509 RNA binding motif protein 10 Rbm10 0,007 0,8 0,1
305606 Hs.89839 EphA1 Epha1 0,007 0,9 0,1
193481 Hs.490394 Single-stranded DNA binding protein 1 Ssbp1 0,007 0,8 0,1
897906 Hs.207459 ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 Siat1 0,007 0,7 0,2
235155* Hs.433300 Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide Fcer1g 0,007 0,9 0,0
308588 Hs.173464 FK506-binding protein 8 (38kD) Fkbp8 0,007 0,8 0,1
753313 Hs.371021 Lysosomal-associated multispanning membrane protein-5 Laptm5 0,007 0,9 0,1
814246 Hs.531089 proteasome (prosome, macropain) subunit, alpha type, 3 Psma3 0,007 0,8 0,1
774036* Hs.190028 Glutathione S-transferase omega 1 Gsto1 0,008 0,8 0,1
208940 Hs.284414 Hydroxysteroid (17-beta) dehydrogenase 13 Scdr9 0,008 0,8 0,1
767769 Hs.334848 hypothetical protein FLJ13291 Flj13291 0,008 0,8 0,1
251135 Hs.523145 dolichyl-diphosphooligosaccharide-protein glycosyltransferase Ddost 0,008 0,8 0,1
786048 Hs.108371 E2F transcription factor 4, p107/p130-binding E2f4 0,008 0,9 0,1
127821 Hs.1211 acid phosphatase 5, tartrate resistant Acp5 0,008 0,7 0,2
470846 Hs.528834 cleavage and polyadenylation specific factor 5, 25 kD subunit Cpsf5 0,009 0,7 0,2
810131 Hs.514167 keratin 19 Krt19 0,009 0,6 0,3
502067 Hs.517761 Lupus brain antigen 1 Lba1 0,009 0,6 0,2
26711 Hs.240770 nuclear cap binding protein subunit 2, 20kD Ncbp2 0,009 0,8 0,1
898123 Hs.473648 phosphoribosylglycinamide formyltransferase Gart 0,009 0,6 0,2
898138 Hs.385986 ubiquitin-conjugating enzyme E2B (RAD6 homolog) Ube2b 0,009 0,8 0,2
* Sequenced clone 
§ Gene probe accociated with multiple clusters
† Gene information changed due to wrong sequence
The table lists all genes differentially regulated in esomeprazole-treated patients. Unigene build 186 was used.
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